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ABSTRACT 89 
Background 90 
Tranexamic acid (TXA) reduces death due to bleeding after trauma and post-partum 91 
haemorrhage. 92 
Objective (s) 93 
The aim was to assess if tranexamic acid is safe, reduces haematoma expansion and improves 94 
outcome in adults with spontaneous intracerebral haemorrhage (ICH). 95 
Design 96 
TICH-2 was a pragmatic phase III prospective double blind randomised placebo-controlled 97 
trial.  98 
Setting: Acute stroke services at 124 hospitals in 12 countries (Denmark, Georgia, Hungary, 99 
Ireland, Italy, Malaysia, Poland, Spain, Sweden, Switzerland, Turkey, and the UK). 100 
Participants: Adult (≥18 years) patients with ICH within 8 hours of onset. Exclusion criteria 101 
were intracerebral haemorrhage secondary to anticoagulation, thrombolysis, trauma, or a 102 
known underlying structural abnormality; patients for whom tranexamic acid was thought to 103 
be contraindicated; prestroke dependence (modified Rankin Scale [mRS] score >4); life 104 
expectancy less than 3 months; and Glasgow Coma Scale score less than 5. 105 
Interventions 106 
Participants received 1g intravenous tranexamic acid bolus followed by an 8 hour 1g 107 
infusion, or matching placebo (saline 0.9%) allocated by randomisation. 108 
Main outcome measures 109 
The primary outcome was functional status (death or dependency) at day 90, measured by 110 
shift in the modified Rankin Scale (mRS), using ordinal logistic regression, with adjustment 111 
for stratification and minimisation criteria. 112 
Results 113 
2,325 participants (TXA 1161, placebo 1164) were recruited from 124 hospitals in 12 114 
countries between 2013 and 2017. Treatment groups were well balanced at baseline.  115 
The primary outcome was determined for 2307 (TXA 1152, placebo 1155 participants. There 116 
was no statistically significant difference between the groups for the primary outcome of 117 
functional status at day 90 (adjusted odds ratio [aOR] 0.88, 95% CI 0.76-1.03, p=0.11).  118 
Although there were fewer deaths by day 7 in the TXA group (aOR 0.73, 95% CI 0.53-0.99, 119 
p=0.041), there was no difference in case fatality at 90 days (adjusted hazard ratio 0.92, 95% 120 
CI 0.77 to 1.10, p =0.37).  121 
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Fewer patients experienced serious adverse events (SAEs) after TXA vs. placebo by days 2 122 
(p=0.027), 7 (p=0.020) and 90 (p=0.039). There was no increase in thromboembolic events or 123 
seizures. 124 
Limitations  125 
Despite attempts to enrol patients rapidly, the majority of participants were enrolled and 126 
treated more than 4.5hours after stroke onset. Pragmatic inclusion criteria lead to a 127 
heterogeneous population some of whom had very large strokes. Although 12 countries 128 
enrolled participants, the majority (82.1%) were from the UK. 129 
Conclusions 130 
There was no significant difference in functional status at 90 days after intracerebral 131 
haemorrhage with tranexamic acid, despite significant modest reductions in early death (by 7 132 
days), haematoma expansion and serious adverse events, consistent with an antifibrinolytic 133 
effect. TXA was safe with no increase in thromboembolic events. 134 
Future work  135 
Future work should focus on enrolling and treating patients early after stroke and identify 136 
which participants are most likely to benefit from haemostatic therapy. Large randomised 137 
trials are needed. 138 
Study registration 139 
TICH-2 Trial is registered with the ISRCTN registry as ISRCTN93732214 on 17th January 140 
2013. 141 
Funding details 142 
The TICH-2 trial was funded by the National Institute for Health Research, Health 143 
Technology Assessment (project number 11_129_109) Pragmatic Trials, UK and Swiss Heart 144 
foundation in Switzerland.  145 
Word count 500/500 146 
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4 Plain English Summary 
 
Background 
Stroke caused by bleeding in the brain (intracerebral haemorrhage, ICH) is a medical 
emergency. Around one-third of such strokes are complicated by continuing bleeding, which 
usually occurs within the first few hours and is associated with death or severe disability. 
Tranexamic acid is a drug that was seen to reduce death from bleeding after trauma and 
childbirth.  
 
Methods 
We enrolled adults within 8 hours of intracerebral haemorrhage into this large randomised 
trial.. Half the participants were given an injection of tranexamic acid and the other half 
placebo (salt water).  The main aim was to measure changes in recovery by a telephone 
questionnaire on how much the person was able to do or needed help with 90 days after the 
stroke (functional status). Other measures included amount of brain bleeding, complications 
after stroke (serious adverse events), drug side effects and death within 7 days of stroke. 
 
Results 
2325 participants from 124 hospitals in 12 countries were enrolled between 2013 and 2017.  
Participants treated with tranexamic acid had no significant difference in functional status 90 
days after stroke. There were small but significant reductions in brain bleeding, death in the 
first 7 days and complications after stroke and tranexamic acid was safe with no increased 
side effects.  
 
Conclusion 
Tranexamic acid did not result in a significant improvement in recovery at 90 days 
(functional status) despite small reductions in early death, brain bleeding and complications. 
Larger trials are needed to confirm if these small benefits with tranexamic acid can 
significantly improve functional status after stroke due to bleeding in the brain.  
  
 13 
5 Scientific Summary  
 
Background 
Although intracerebral haemorrhage (ICH), only accounts for 10 to 15% of all strokes, it  is 
the most devastating type of stroke with a 30-day fatality rate of 40 to 50%. Seventy to 80% 
of survivors remained dependent one year after ICH.  
 
Haematoma expansion occurs in up to 38% of patients with ICH, mostly within the first few 
hours. Haematoma expansion leads to higher mortality and worse functional outcome. The 
most widely researched haemostatic agent in ICH, recombinant factor VIIa (rFVIIa), did not 
significantly reduced death or dependency. Although a reduction in haematoma expansion 
was reported, the benefit of this was likely offset by an increase in thromboembolic events.  
Tranexamic acid is an antifibrinolytic agent that acts on plasmin-mediated pathway to prevent 
breakdown of clot. It is an effective haemostatic agent in many bleeding conditions. In the 
CRASH-2 trial involving 20,211 patients with major bleeding due to trauma, tranexamic acid 
significantly reduced mortality, OR 0.91 (0.85-0.97), especially when given within 3 hours of 
trauma. A subgroup analysis of patients with traumatic intracranial haemorrhage in the trial 
showed a non-significant trend to reduced mortality, OR 0.47 (0.21-1.04), and death of 
dependency, OR 0.66 (0.32-1.36).  The CRASH-3 is an ongoing randomised controlled trial 
that assess the effect of tranexamic acid on risk of death or disability in patients with 
traumatic brain injury.  
 
Tranexamic acid reduced bleeding related death in women with postpartum haemorrhage in 
the WOMAN trial (n=20,060), RR 0.81 (0.65–1.00), with the effect greatest in patients given 
treatment within 3 hours of childbirth, RR 0.69 (0.52–0.91). Furthermore, an individual 
patient data meta-analysis of CRASH-2 and WOMAN trial highlights the need to administer 
tranexamic acid immediately. Immediate treatment improved survival by more than 70% and 
the survival benefit decreased by 10% for every 15 min of treatment delay until 3 h, after 
which there was no benefit. There was no increase of thromboembolic events with 
tranexamic acid in both trials, although the patients were younger and had less co-morbidities 
than those with ICH. 
 
The use of tranexamic acid in spontaneous ICH has been studied in two small RCTs. The 
Tranexamic acid in IntraCerebral Haemorrhage (TICH) trial was a feasibility trial that 
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randomised 24 patients to received intravenous tranexamic acid or placebo. Arumugam 2015 
was a single centre, single-blind RCT that allocated 30 patients to intravenous tranexamic 
acid or placebo. Two recent systematic reviews concluded that there is no evidence for 
tranexamic acid treatment in spontaneous ICH although there are six ongoing RCTs including 
TICH-2. 
 
Objectives 
The primary objective of the trial was to assess whether tranexamic acid is safe and improves 
functional status (reduces death and dependency) after spontaneous ICH. The secondary 
objective was to assess the effect of tranexamic acid on secondary outcomes: clinical 
outcomes (disability, quality of life, mood, cognition), safety outcomes, costs and 
radiological efficacy.  
 
Methods 
TICH-2 was an international double-blind randomised placebo-controlled phase III trial. The 
trial included adult patients (>18 years) with spontaneous ICH presenting within 8 hours of 
symptoms onset. Exclusion criteria were intracerebral haemorrhage secondary to 
anticoagulation, thrombolysis, trauma, or a known underlying structural abnormality; patients 
for whom tranexamic acid was contraindicated; prestroke dependence (modified Rankin 
Scale [mRS] score >4); life expectancy less than 3 months; and Glasgow Coma Scale score 
less than 5. Patients were recruited by investigators from acute stroke services in 124 
hospitals in 12 countries. Ethical approval was obtained in each site and country prior to 
commencement of the study. The study was designed to be performed in two phases: an 18 
month start-up phase (aim activate 30 centres, recruit a minimum of 300 participants) then 
main phase (120 centres, recruit to a total of 2,000 participants) with no break in recruitment 
between the two phases as the pre-specified stopping criteria were not met. 
Investigators obtained written informed consent from each participant if they had the capacity 
to provide it. If participants could not give consent, a relative or representative gave proxy 
consent. When consent was deferred or given by a proxy, we informed the participant about 
the trial as soon as possible and sought their consent for on-going follow-up. 
 
Participants were randomised centrally using a secure internet site in real-time. 
Randomisation involved stratification by country and minimisation on key prognostic factors: 
age; sex; time since onset; systolic blood pressure; stroke severity (NIHSS); presence of 
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intraventricular haemorrhage; known history antiplatelet treatment used immediately prior to 
stroke onset. Participants were assigned to receive intravenous tranexamic acid 1 g loading 
dose in 100 mL normal saline 0.9% infused over 10 min, followed by another 1 g in 250 mL 
normal saline 0.9%, which was infused over 8 h or a matching placebo (normal saline 0.9%), 
administered with an identical regimen. Individual masked treatment packs containing four 5 
mL glass ampoules of tranexamic acid 500 mg or sodium chloride 0.9%, which were made 
identical in appearance and were labelled with a unique pack number. The randomisation 
system allocated each participant a unique number corresponding to a treatment pack 
containing either tranexamic acid or placebo. Treatment allocation was concealed from all 
staff and patients involved in the trial. 
 
At randomisation, investigators recorded the participants’ age, sex, and medical history, as 
well as their assessment of intracerebral haemorrhage location, presence of intraventricular 
haemorrhage, whether advanced imaging had been performed and if applicable presence of 
spot sign. Investigators assessed prestroke dependence with the mRS, and stroke severity 
using the NIHSS and Glasgow Coma Scale. Participants were reviewed at day 2, day 7, and 
on the day of death or hospital discharge, whichever came first, to gather information on 
clinical assessment (NIHSS), the process of care measures (e.g., blood pressure lowering 
treatment, neurosurgical intervention), and discharge date and destination (e.g., home or 
institution). 
 
Central assessors, who were trained and certified in administration of the mRS and masked to 
treatment allocation, did the final follow-up at 90 days by telephone from the coordinating 
centre in each country. If the participant or carer could not be contacted, they received a 
questionnaire covering the same outcome measures by post.  
 
Brain imaging by CT was done as part of routine care before enrolment; a second research 
CT scan was done 24 hours after treatment to assess haematoma expansion. When multiple 
scans were done, the scan closest to 24 h after randomisation was used. Central independent 
expert assessors, who were masked to treatment assignment, assessed CT scans for the 
location of the intracerebral haemorrhage using a web-based adjudication system. Semi-
automated segmentation of the intracerebral haemorrhage was done on Digital Imaging and 
Communications in Medicine-compliant images to give intracerebral haemorrhage volumes. 
The user-guided three-dimensional active contour tool in the ITK-SNAP software (version 
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3.6) was used for segmentation and one of three assessors did manual editing as required. All 
assessments were masked to treatment assignment. Haematoma expansion was defined as an 
absolute increase of more than 6 mL or a relative growth of greater than 33%. 
 
The primary outcome was functional status at day 90, as assessed with the mRS, which was 
administered by telephone or postal questionnaire and masked to treatment allocation. 
Secondary outcomes included neurological impairment at day 7 or discharge (whichever 
came first) assessed with the NIHSS, health-related quality of life measured with EuroQoL-5 
dimensions (EQ-5D) health utility status and visual analogue scale, activities of daily living 
according to the Barthel index, cognition assessed via a modified Telephone Interview for 
Cognitive Status (TICS-M) and verbal fluency, mood assessed with the Zung depression 
scale (ZDS), costs (length of hospital stay and discharge destination), and radiological 
efficacy (change in haematoma volume from baseline to 24 h and haematoma expansion). 
Prespecified safety outcomes were death, venous thromboembolism, ischaemic events 
(stroke, transient ischaemic attack, myocardial infarction, acute coronary syndrome, 
peripheral artery disease), and seizures. These were reported up to day 90, along with all 
serious adverse events in the first 7 days. Safety outcomes and serious adverse events were 
independently adjudicated masked to treatment assignment. Serious adverse events were 
categorised in accordance with the medical dictionary for regulatory authorities (MeDRA). 
 
Results 
2325 participants were recruited from 124 hospitals in 12 countries over 55 months. 1161 
participants were randomly assigned to receive tranexamic acid and 1164 to receive placebo. 
Most participants were recruited in the UK (1910, 82%). The mean age was 68.9 years (SD 
13.8) and 1301 (56%) participants were male. The median time from stroke onset to 
randomisation was 3.6 h (IQR 2.6–5.0) and 833 (36%) participants were recruited within 3 h. 
Mean baseline systolic blood pressure was 173 mm Hg (SD 27.5) and diastolic blood 
pressure was 93 mm Hg (18.4). 1371 (59%) participants had a haematoma that was 
supratentorial deep, whereas 738 (32%) had one that was supratentorial lobar; 745 (32%) 
participants had intraventricular haemorrhage. Mean haematoma volume was 24.0 mL (SD 
27.2) and median haematoma volume was 14.1 mL (IQR 5.9–32.4). Contrast-enhanced 
imaging in the form of CTA was done in 249 (11%) participants. Of these individuals, 24 
(20%) of 121 in the tranexamic acid group and 32 (25%) of 128 in the placebo group were 
spot positive. Treatment groups were well balanced at baseline. 
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The primary outcome of mRS at day 90 was assessed in 2307 (99%) of 2325 participants; 
nine (<1%) were lost to follow-up and nine (<1%) withdrew from follow-up. There was no 
difference in the distribution in the mRS at day 90 after adjustment for stratification and 
minimisation criteria, with an adjusted odds ratio (aOR) of 0.88 (95% CI 0.76–1.03, p=0.11). 
A formal goodness-of-fit test showed no evidence that the proportional odds assumption was 
violated (p=0.97). In a sensitivity analysis, we detected no difference between the groups in 
the proportion of participants who were dead or dependent at day 90 (mRS >3) and the aOR 
was 0.82 (95% CI 0.65–1.03, p=0.08). In the prespecified subgroup analysis, the only 
significant interaction was between mRS and baseline systolic blood pressure (SBP, 
interaction p=0.019) participants with a baseline SBP ≤ 170 mm Hg had a favourable shift in 
mRS with tranexamic acid compared with those with a SBP > 170 mm Hg. There was no 
heterogeneity of treatment effect by time of administration, whether dichotomised as less 
than 3 h versus 3 h or longer (interaction p=0.75) or as less than 4.5 h versus 4.5 h or longer 
(interaction p=0.28) or when analysed as a continuous variable (aOR 0.98, 95% CI 0.90–
1.07, p=0.69). 
 
Fewer participants had haematoma expansion at day 2 in the tranexamic acid group (265 
[25%] of 1054 participants) than in the placebo group (304 [29%] of 1058 participants; aOR 
0.80, 95% CI 0.66 to 0.98, p=0.030). The mean increase in haematoma volume from baseline 
to 24 h was also less in the tranexamic acid group (3.72 mL, SD 15.9) than in the placebo 
group (4.90 mL, 16.0; adjusted mean difference –1.37, 95% CI –2.71 to –0.04, p=0.043).  
Neurological impairment (mean NIHSS score) at day 7 did not differ between the tranexamic 
acid group and placebo group (adjusted mean difference –0.43, 95% CI –0.94 to 0.09; 
p=0.10). 
 
There were no significant differences in any of the day 90 functional outcomes between 
treatment groups— i.e., activities of daily living, mood, cognition, or quality of life. Length 
of hospital stay and discharge disposition did not differ between treatment groups. 
 
By day 7, fewer patients had died in the tranexamic acid group (101 [9%] of 1161) than in the 
placebo group (123 [11%] of 1164; table 2). However, the numbers of deaths by day 90 did 
not differ between the tranexamic acid group (250 [22%] patients) and the placebo group 
(249 [21%] patients; table 2). Survival did not differ between the treatment groups over 90 
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days (adjusted hazard ratio 0.92, 95% CI 0.77–1.10, p=0.37).  
 
Participants in the tranexamic acid group had fewer predefined safety outcomes and serious 
adverse events than those in the placebo group at day 2 (379 [33%] patients vs 417 [36%] 
patients, p=0.027), day 7 (456 [39%] vs 497 [43%], p=0.020), and 90 days (521 [45%] vs 556 
[48%], p=0.039). There was no increase in venous thromboembolic events (39 [3%] patients 
in the tranexamic acid group vs 37 [3%] in the placebo group; p=0.98), seizures or arterial 
occlusions (myocardial infarction, acute coronary syndrome, or peripheral arterial occlusion) 
in the tranexamic acid group compared with the placebo group.  
 
Conclusions 
Tranexamic acid did not have significant benefit on functional status at day 90, although 
potential benefits were seen with significant modest reductions in haematoma expansion, 
early death, and serious adverse events. The observed effect size was smaller than anticipated 
and is compatible with a lack of efficacy or the presence of a smaller treatment effect than 
expected. 
 
Implications for healthcare 
Based on current evidence, tranexamic acid cannot be recommended for routine treatment of 
patients with spontaneous ICH. Tranexamic acid is inexpensive, easy to administer, seems to 
be safe, and is widely available, so even a modest treatment effect could have an important 
impact on the global scale. 
 
Recommendations for research 
Although there is insufficient evidence to support the routine use of tranexamic acid in 
clinical practice for spontaneous intracerebral haemorrhage, the results do not exclude a 
modest beneficial effect. The reductions in haematoma expansion and early deaths may 
reflect antifibrinolytic effect and are promising, but further large randomised trials are needed 
to confirm or refute a clinically significant treatment effect. Future research should focus on 
enrolling participants earlier after ICH onset and investigate which subgroups of patients are 
most likely to benefit. 
 
ISRCTN registration 
The trial is registered with the ISRCTN registry, number ISRCTN93732214. 
 19 
 
Funding details 
The TICH-2 trial was funded by the National Institute for Health Research, Health 
Technology Assessment (project number 11_129_109) Pragmatic Trials, UK and Swiss Heart 
foundation in Switzerland.  
 
Word count 2233/2400 
  
 20 
 
6 INTRODUCTION 
 
6.1 Scientific background 
6.1.1 Haemorrhagic stroke 
Haemorrhagic stroke, or intracerebral haemorrhage caused by bleeding in the brain, can be 
devastating and is a common cause of death and disability, both in the UK and worldwide.1 
Despite development of effective treatments for ischaemic stroke (thrombolysis, mechanical 
thrombectomy, aspirin, hemicraniectomy) there is no proven effective treatment for 
spontaneous intracerebral haemorrhage (SICH). 
 
6.1.2 Haematoma expansion 
Outcome after intracerebral haemorrhage is closely related to whether brain bleeding expands 
after onset, so called haematoma expansion, or whether re-bleeding occurs; both are associated 
with a bad outcome (death and disability).2, 3 Contrast extravasation during contrast-enhanced 
CT and CT angiography, known as the spot sign, have been shown to predict haematoma 
expansion.4 Nevertheless there is currently wide variation in the use of these techniques in 
routine clinical practice. 
 
Haematoma expansion is related to both haemostatic factors and blood pressure; furthermore, 
haematoma volume can be reduced surgically - all these approaches are potential targets for 
treatment in intracerebral haemorrhage.  
 
6.1.3 Intensive blood pressure treatment 
Lowering blood pressure in patients with intracerebral haemorrhage is a potential therapeutic 
option to limit haematoma expansion and improve outcome. The INTERACT trial assessed 
intensive blood pressure treatment in 404 intracerebral haemorrhage patients. The study 
showed that aggressively lowering blood pressure appears safe and may limit haematoma 
expansion, but did not change outcome.5 In the INTERACT-2 trial, the largest intervention 
trial of SICH which involved 2839 patients, intensive blood pressure lowering to systolic 
blood pressure (SBP) of <140 mmHg is safe and resulted in significant shift in ordinal 
analysis of the modified Rankin Scale, although there was no significant improvement in 
primary outcome of death and disability (mRS 3 to 6).6 In view of this result, the European 
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Stroke Organisation (ESO) guideline in 2014 and American Heart Association/ American 
Stroke Association (AHA/ASA) guideline in 2015 suggest lowering BP to SBP of 140 
mmHg is safe and may have a beneficial effect on functional outcome.7, 8 
 
The most recent development of BP treatment in SICH is the ATACH-2 trial, which was 
stopped early in view of futility after recruiting 1000 patients. There was no significant 
difference in death or dependency between the intensive and guideline treatment groups. In 
addition, there were higher renal adverse events in those treated with intensive BP reduction.9 
There are several potential reasons why ATACH-2 had different findings compared to 
previous trials. Patients in the trial received intravenous antihypertensive medication pre-
randomisation to ensure compliance with guidelines. Furthermore, the BP reduction was 
much larger than seen in previous trials – from a baseline SBP of approximately 200 mmHg, 
the intensive arm achieved a mean minimum SBP of 129 mmHg, while the standard 
treatment arm attained a mean minimum SBP of 141 mmHg. In contrast, the baseline BP was 
approximately 179 mmHg in INTERACT-2, with the intensive and standard treatment groups 
achieving a SBP of 150 mmHg and 164 mmHg at 1 hour post randomisation, respectively. 
These results suggest that the degree of BP reduction in the standard arm of ATACH-2 is 
similar to the intensive arm of INTERACT-2.10 In addition, all patients in ATACH-2 were 
treated with intravenous nicardipine, which has a weak antiplatelet effect, possibly negating 
the benefit achieved by BP reduction.10, 11 The UK national clinical guideline for stroke 2016 
recommends lowering blood pressure to SBP of 140 mmHg, while the latest American 
guideline in 2017 suggest lowering to SBP of <140 mmHg may be harmful.12, 13 
 
6.1.4 Surgery for intracerebral haemorrhage 
The current role of surgery is limited to patients with cerebellar haematoma. Posterior 
decompression in patients with cerebellar haematoma of > 3cm and that result in 
hydrocephalus or brainstem compression is lifesaving.14, 15 In addition, in ICH complicated 
with hydrocephalus, the placement of an external ventricular drain lowers intracranial 
pressure and may reduce mortality. 16 
 
The role of routine surgery in patients with supratentorial haematoma is unclear. The 
International Surgical Trial in Intracerebral Haemorrhage (STICH) trial is a prospective 
open-label blinded endpoint randomised controlled trial that randomised 1033 patients with 
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ICH to early surgical haematoma evacuation and initial conservative treatment. There was no 
significant difference in outcome between the two groups.17 This may be because patients 
were only recruited when the surgeon was in equipoise and time to surgery was delayed 
(mean time 30 hours) and thus surgery was unlikely to be able to limit haematoma expansion. 
However, a subgroup analysis of the trial showed that patients with superficial haematoma 
(<1cm from surface) benefited from early surgery. The trial also found that patients with poor 
initial GCS of <8 and intraventricular haemorrhage had poor outcome despite surgery.17  
 
The subsequent Early surgery versus initial conservative treatment in patients with 
spontaneous supratentorial lobar intracerebral haematomas (STICH II) trial randomised 601 
patients with superficial lobar haematoma, with haematoma volume of 10 to 100 mL and 
without intraventricular extension to undergo early surgery or initial conservative 
management. There was an absolute reduction in mortality of 6% and 4% increase in 
favourable outcome in the early surgery arm though the difference was not statistically 
significant.18 One reason that may explain this neutral result is that the trial recruited patients 
who were conscious or mildly confused that might not benefit from surgery. Patients with 
poorer GCS of between 9 to 12 benefited from early surgery.18 A meta-analysis including 
STICH II and 14 other trials (3366 patients) concluded overall benefit for early surgery (OR 
0.74; 95% CI 0.64–0.86).18 However, the meta-analysis should be interpreted discreetly as 
there was significant heterogeneity in the trials. It is unclear whether surgical intervention 
benefited certain subgroup of patients. Current ESO guideline does not recommend routine 
surgery for supratentorial haematoma, though early surgery may be considered in patients 
with GCS of 9-12.7 Similarly the AHA/ASA guideline does not recommend routine surgery 
for supratentorial haematoma except in patients who are deteriorating.8 
 
6.1.5 Haemostatic therapy 
In anticoagulant-related ICH, haemostatic therapy plays an important role. In vitamin K 
antagonist-related ICH, 4-factor prothrombin complex concentrate (PCC) normalised 
international normalised ratio (INR) to <1.2 within 3 hours in 67% compared to only 9% with 
fresh frozen plasma (FFP).19 Where 4-factor PCC is not available, FFP can be given as an 
alternative. In addition, intravenous vitamin K should be given as well. In ICH related to 
direct oral anticoagulants (DOAC-dabigatran, rivaroxaban, apixaban, edoxaban) reversal 
agents are now available. Idarucizumab is a specific reversal agent for the direct thrombin 
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inhibitor, dabigatran.20 Idarucizumab normalises diluted thrombin time and ecarin thrombin 
time within 15 minutes in almost 100% of patients.20 Andexanet, a reversal agent for direct 
(rivaroxaban, apixaban, edoxaban) and indirect factor Xa inhibitor (enoxaparin) was found to 
reverse the anti-Xa activities of rivaroxaban and apixaban within minutes of administration. It 
was tested in a single-arm study amongst 67 patients who had intracranial and other major 
bleeding secondary to rivaroxaban, apixaban and enoxaparin. Effective haemostasis was 
achieved in 79% of the patients within 12 hours. However, 18% (12/67) of the patients had 
thromboembolic events.21 Andexanet alfa has been approved as a reversal agent by US FDA 
in May 2018. The role of an antifibrinolytic agent, tranexamic acid in DOAC-related ICH is 
being examined. 
 
The role of haemostatic therapy in ICH not related to anticoagulant is less clear. The most 
widely studied agent was recombinant factor VIIa (rFVIIa). In a phase IIb trial with 399 
patients, rFVIIa restricted haematoma expansion, improved functional outcome and reduced 
mortality despite a significant increase in arterial thromboembolic events.22 However in a 
larger phase III study in 841 patients, rFVIIa had no effect on functional outcome or mortality 
despite restricting haematoma expansion.23 A meta-analysis comparing blood clotting factors 
versus placebo or open control, including 1480 patients from 7 randomised controlled trials 
(RCTs) found no significant benefit on mortality, or death or dependency.24 There was a 
trend to improved outcome which was offset by an increase in thromboembolic events. Two 
RCTs recruited only ICH patients with positive CTA spot sign, i.e. those at risk of 
haematoma expansion and most likely to benefit from rFVIIa.25, 26 However, the trials were 
stopped due to poor recruitment and had not been published yet other than in abstract form.27  
Platelet transfusion in antiplatelet-related ICH was found to be harmful in the Platelet 
transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage 
associated with antiplatelet therapy (PATCH) trial. The odds of death or dependence at 3 
months were higher in the platelet transfusion group than in the standard care group (adjusted 
common odds ratio 2.05, 95% CI 1.18–3.56; p=0.011).28  
 
6.1.6 Tranexamic acid 
Tranexamic acid is a licensed anti-fibrinolytic drug that can be administered intravenously or 
orally and is used in a number of bleeding conditions to reduce bleeding. In the CRASH-2 
trial involving 20,000 patients with major bleeding following trauma, tranexamic acid 
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significantly reduced mortality, OR 0.91 (0.85-0.97), with no increase in vascular occlusive 
events. Treatment was most effective when given rapidly; delayed administration was 
associated with lack of efficacy and potential harm. In a subgroup analysis of patients with 
traumatic ICH, tranexamic acid showed a non-significant trend to reduced mortality, OR 0.47 
(0.21-1.04), and death or dependency, OR 0.66 (0.32-1.36). However, patients in CRASH-2 
were younger and had less co-morbidities than those with SICH. In another randomised 
controlled trial in traumatic intracerebral haemorrhage, tranexamic acid reduced death, OR 
0.69 (0.35 -1.39), and death or dependency, 0.76 (0.46 – 1.27), without increased 
thromboembolic events. A meta-analysis of tranexamic acid in traumatic intracranial 
haemorrhage showed that it was associated with a significant reduction in subsequent 
intracranial bleeding and a larger trial is ongoing.29, 30  
 
In the WOMAN trial involving 20,060 women, tranexamic acid reduced death due to 
bleeding in women with post-partum haemorrhage (risk ratio [RR] 0.81, 95% CI 0.65–1.00; 
p=0.045), with the effect greatest in patients given treatment within 3 hours of childbirth (RR 
0.69, 95% CI 0.52–0.91; p=0.008).31 The need to administer tranexamic acid immediately in 
bleeding conditions was again highlighted in an individual patient data meta-analysis 
combining data from the CRASH-2 and WOMAN trial. Immediate treatment improved 
survival by more than 70% (OR 1.72, 95% CI 1.42–2.10; p<0.0001) and the survival benefit 
decreased by 10% for every 15 min of treatment delay until 3 h, after which there was no 
benefit.32  
 
Tranexamic acid has been tested in aneurysmal subarachnoid haemorrhage, where it reduced 
the risk of re-bleeding at the expense of increased risk of cerebral ischaemia.33 However, many 
of the trials of tranexamic acid in subarachnoid haemorrhage involved giving high doses of up 
to 6 g per day for a prolonged duration of three to six weeks and this could have accounted for 
the increased ischaemic events.33  
 
Tranexamic acid has been found to restrict haematoma expansion in acute SICH in a small 
non randomised study, although this did not report on safety.34 In another small study 
(n=156), rapid administration of a bolus of tranexamic acid within 24 hours of stroke was 
observed to reduce haematoma expansion (17.5% vs. 4.3%).35 In this study, tranexamic acid 
was given in combination with intensive blood pressure control, suggesting that it may be 
possible to combine haemostatic and haemodynamic approaches. The authors subsequently 
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reported a study of additional 95 patients treated with rapid infusion of tranexamic acid with 
HE occurring in 4.2% of these patients.36  
 
6.1.7 Systematic review of RCTs of TXA in ICH 
We searched the Cochrane Stroke Trials register; the Cochrane Central Register of Controlled 
Trials; MEDLINE Ovid and Embase Ovid to 27 November 2017 for randomised controlled 
trials of antifibrinolytics and tranexamic acid. Search terms have been published previously.24 
To identify further published, ongoing and unpublished randomised controlled trials (RCTs) 
we scanned bibliographies of relevant articles and searched international registers of clinical 
trials in November 2017. We searched for trials in all languages. Quality of evidence was 
assessed using the GRADE approach. We found 2 small randomised controlled trials of TXA 
with a total of 54 participants, with no clear evidence of benefit or harm associated with 
tranexamic acid.37, 38 Systematic review therefore concluded that there is a lack of evidence 
for use of tranexamic acid in spontaneous ICH. Five further randomised controlled trials were 
on-going.24, 39  
 
6.2 Rationale for trial 
Haematoma expansion is a not uncommon complication of intracerebral haemorrhage and is 
associated with devastating consequences of early death and severe disability in those who 
survive. There is no effective drug treatment to prevent haematoma expansion. Tranexamic 
acid, an antifibrinolytic drug, is effective at reducing bleeding and death due to bleeding in 
other conditions. Tranexamic is widely available, affordable and appears to be safe in studies 
in other bleeding conditions conducted to date. The rationale for this study was to test the 
safety and efficacy of tranexamic acid in intracerebral haemorrhage, the hypothesis being that 
tranexamic acid will prevent haematoma expansion and reduce death and disability after ICH.  
 
7 METHODS 
 
7.1 Objectives 
7.1.1 Purpose 
To assess in a pragmatic phase III prospective double blind randomised placebo-controlled 
trial whether tranexamic acid is safe and reduces death or dependency after spontaneous 
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intracerebral haemorrhage (SICH). The results will determine whether tranexamic acid 
should be used to treat SICH, which currently has no proven therapy. 
 
7.1.2 Primary Objective 
To assess whether tranexamic acid is safe and improves functional status (reduces death and 
dependency) after spontaneous intracerebral haemorrhage (SICH). 
 
7.1.3 Secondary Objectives 
To assess the effect of tranexamic acid on secondary outcomes: clinical outcomes, safety 
outcomes, costs and radiological efficacy.  
 
7.2 Design 
TICH-2 was an international double-blind randomised placebo-controlled parallel group, 
phase III trial performed in two phases: an 18 month start up phase (aim activate 30 centres, 
recruit a minimum of 300 participants) then main phase (120 centres, recruit to a total of 
2,000 participants). There was no break in recruitment as the trial proceeded from the start up 
phase to the main phase as the stopping criteria we not met. 
 
Participants were enrolled by investigators from acute stroke units at 124 hospital sites in 12 
countries; Denmark, Georgia, Hungary, Ireland, Italy, Malaysia, Poland, Spain, Sweden, 
Switzerland, Turkey and United Kingdom. Ethics approval was obtained in each site and 
country prior to commencement of the study. The trial was adopted in the UK by the National 
Institute Health Research Clinical Research Network, and registered as ISRCTN93732214. 
The full TICH-2 trial protocol and statistical plan have been published. 
 
7.3 Study settings 
Setting acute stroke units at 124 hospitals in 12 countries (Denmark, Georgia, Hungary, 
Ireland, Italy, Malaysia, Poland, Spain, Sweden, Switzerland, Turkey, and the UK). Full 
listing of sites and investigators can be found as supplementary data. 
 
7.4 Participants 
7.4.1 Inclusion criteria 
Adult (≥18 years) patients with acute SICH within 8 hours of stroke onset. (Where stroke 
onset time is unknown, the time of when last known well was used.) 
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7.4.2 Exclusion criteria 
Patients with intracerebral haemorrhage secondary to anticoagulation, thrombolysis or known 
underlying structural abnormality such as arterial venous malformation, aneurysm, tumour, 
trauma, venous thrombosis as cause for the intracerebral haemorrhage. Note it was not 
necessary for investigators to exclude underlying structural abnormality prior to enrolment, 
but where an underlying structural abnormality was already known, these patients should not 
be recruited. 
 
Other exclusion criteria were patients for whom tranexamic acid is thought to be 
contraindicated, patients with pre-morbid dependency (mRS>4), pre-stroke life expectancy 
<3 months (e.g. advanced metastatic cancer), Glasgow coma scale <5, female patient of 
childbearing potential either pregnant or breastfeeding at randomisation, geographical or 
other factors that prohibited follow up at 90 days e.g. no fixed address or telephone contact 
number, or overseas visitor, and participation in another drug or devices trial concurrently, 
with the exception of the secondary prevention trial, RESTART. 
 
7.5 Data collected at baseline  
Investigators recorded the participants’ age, sex, ethnic group, medical history and whether 
they were taking antiplatelet agents, as well as their assessment of intracerebral haemorrhage 
location, intraventricular haemorrhage, spot sign and blood pressure. Investigators assessed 
prestroke dependence with the mRS, and stroke severity using the NIHSS and Glasgow 
Coma Scale.  
 
7.6 Interventions  
The intervention, tranexamic acid, was given intravenously as a 1 g loading dose in 100 mL 
normal saline 0.9% infused over 10 min, followed by another 1 g in 250 mL normal saline 
0.9%, which was infused over 8 h. The comparator was a matching placebo (normal saline 
0.9%), administered with an identical regimen.  
 
The dosing regimen chosen (1g bolus and 1g infusion) was chosen to achieve plasma 
concentrations sufficient to inhibit fibrinolysis. Studies in cardiac surgery have shown that 
use of a dose greater than 10mg/kg bolus and 1mg/kg infusion does not provide any 
additional haemostatic benefit.40 In the emergency situation administration of a fixed dose is 
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more practicable and the fixed dose chosen is efficacious for large patients (>100 kg) and 
safe for small patients (<50 kg). The short duration of treatment allows for the full effect of 
tranexamic acid on the immediate risk of haematoma expansion without extending too far 
into the acute phase response seen after stroke. 
 
7.7 Randomisation 
All participants eligible for inclusion were randomised centrally using a secure internet site in 
real-time. Randomisation involved stratification by country and minimisation on key 
prognostic factors: age; sex; time since onset; systolic blood pressure; stroke severity 
(NIHSS); presence of intraventricular haemorrhage; known history antiplatelet treatment 
used immediately prior to stroke onset. This approach ensured concealment of allocation, 
minimises differences in key baseline prognostic variables, and slightly improves statistical 
power.  
 
Randomisation allocated a number corresponding to a treatment pack and the participants 
received treatment from the allocated numbered pack. 
In the event of computer failure (for example: server failure), investigators would follow the 
working practice document for computer system disaster recovery, which will allow the 
participant to be randomised manually following standardised operating procedure. 
 
7.8 Blinding 
Clinicians, patients and outcome assessors (research nurse and radiologist) were blinded to 
treatment allocation. In general there should be no need to unblind the allocated treatment. If 
some contra-indication to antifibrinolytic therapy developed after randomisation (e.g. clinical 
evidence of thrombosis), the trial treatment would simply be stopped. Unblinding should be 
done only in those rare cases when the doctor believes that clinical management depends 
importantly upon knowledge of whether the patient received antifibrinolytic or placebo. In 
those few cases when urgent unblinding was considered necessary, the emergency telephone 
number was telephoned, giving the name of the doctor authorising unblinding and the 
treatment pack number. The caller was then told whether the patient received antifibrinolytic 
or placebo. The rate of unblinding was monitored and audited. 
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In the event of breaking the treatment code this was recorded as part of managing a SAE (see 
below for more details) and such actions were reported in a timely manner. The Chief 
Investigator (delegated the sponsor’s responsibilities) was informed immediately (within 24 
hours) of any serious adverse events and determined seriousness and causality in conjunction 
with any treating medical practitioners 
 
7.9 Adherence  
Adherence was assessed by examining the participant’s drug chart and recording the trial 
treatment administered at day 2 (i.e., whether all treatment was given, the time and date of the 
two doses, and any other comments). Adherence was verified by both central review of the 
drug chart and pharmacies recording returns of residual or unused trial medications. 
 
7.10 Assessments after randomisation  
Participants were reviewed at day 2, day 7, and on the day of death or hospital discharge, 
whichever came first, to gather information on clinical assessment (NIHSS), the process of 
care measures (e.g., blood pressure lowering treatment, neurosurgical intervention), and 
discharge date and destination (e.g., home or institution). A second research CT scan was 
done after 24 hours of treatment to assess haematoma expansion. 
 
Central assessors, who were trained and certified in administration of the mRS and masked to 
treatment allocation, did the final follow-up at 90 days by telephone from the coordinating 
centre in each country. If the participant or carer could not be contacted, they received a 
questionnaire covering the same outcome measures by post. 
 
7.11 Primary efficacy outcome 
Functional status, death or dependency (ordinal shift on mRS) at day 90 was compared 
between tranexamic acid and placebo by intention-to-treat using ordinal logistic regression 
(OLR), with adjustment for stratification and minimisation factors. The assumption of 
proportional odds was tested using the likelihood ratio test.  
 
7.12 Secondary outcomes: 
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7.12.1 Clinical 
Clinical outcomes: Neurological impairment (NIHSS41) at day 7 (or discharge if sooner). Day 
90 Outcomes: Disability (Barthel index42), dependency ( mRS43), Quality of Life (EuroQol, 
EQ-5D and EQ-VAS44), Cognition (Telephone Interview Cognition Score-Modified45) and 
mood (Zung Depression Scale46).  
 
7.12.2 Costs 
Cost outcomes: Length of stay in hospital, re-admission, institutionalisation. 
 
7.12.3  Radiological 
Radiological outcomes: relative and absolute haematoma growth and haematoma expansion. 
  
7.12.4 Safety 
Safety outcomes: Death (cause); venous thromboembolism; vascular occlusive events 
(stroke/transient ischaemic attack/myocardial infarction/peripheral artery disease); seizures. 
Serious adverse events in first 7 days.  In addition, we assessed for any safety interaction 
between the treatment effect and time to randomisation. Definitions of evidence required for 
adjudication of safety outcomes can be found in the Appendix 2. 
 
7.13 Study oversight   
The trial was overseen by a trial steering committee, and an international advisory committee 
consisting of each national coordinator. A trial management committee based at the Stroke 
Trials Unit in Nottingham, UK, was responsible for day-to-day conduct of the trial. Study 
data were collected, monitored, and analysed in Nottingham. The trial was performed 
according to the principles of good clinical practice and Declaration of Helsinki.  
 
7.14 Data Monitoring Committee 
An independent Data Monitoring Committee (DSMC) was established. The DSMC received 
safety reports every six months, and performed a total of 6 unblinded reviews of efficacy and 
safety data. The DSMC performed a formal interim analysis after 818 participants had been 
recruited (comprising both trial phases) and followed-up at 90 days. 
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A DSMC Charter was prepared containing details of membership, terms and conditions and 
full details of stopping guidelines. The DSMC reported their assessment to the independent 
chair of the TSC who reported to the HTA. 
 
7.15 Missing data 
Any missing data were reported. For participants to have been included in the primary 
analysis they must have had their mRS score at day 90 recorded along with values for all of 
the minimisation criteria; if not then they were excluded from the analysis. To include as 
many of the participants as possible, we backfilled any missing minimisation criteria from 
their randomisation form. The first step was to contact the recruiting centre and ask if they 
had this information, if not then imputation was used. If any of the individual NIHSS 
measures were missing then the highest risk value was imputed to ensure that a total NIHSS 
could be calculated for each participant. If the history of antiplatelets was not known and 
could not be found then the highest risk value was imputed, as would have been used in the 
randomisation process. Participants died before day 90 were given death scores for outcome 
measures; mRS = 6, EQ-5D = 0, Barthel index = -5, EQ-VAS = -1, TICS-M = -1, animal 
naming = -1, Zung = 102.5a mRS score of 6 and an EQ-5D score of 0. Missing outcome data 
from other follow-ups were excluded from any analyses. If a participant withdrew consent no 
further information was collected; however, data collected thus far from follow-ups was used 
for any of the analyses. 
 
7.16 Statistical analysis 
Statistical analyses were performed according to the published statistical analysis plan by 
Katie Flaherty and Polly Scutt, with oversight by Stuart J Pocock using SAS software 
(version 9.4). Analyses were by intention to treat for all comparisons. Data shown are number 
(%), median [interquartile range, mean (standard deviation) and odds ratio (95% confidence 
intervals). 
 
Death or dependency (ordinal shift on mRS) at day 90 was analysed between tranexamic acid 
and placebo by intention-to-treat using ordinal logistic regression, with adjustment for 
stratification and minimisation factors, which include: age (<70, ≥70), sex (female, male), 
time from stroke onset to randomisation (<3 hours, ≥3 hours), mean systolic blood pressure 
(<170, ≥170), stroke severity (NIHSS<15, ≥15), presence of IVH (no, yes), known history of 
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antiplatelet therapy used prior to stroke onset (no, yes) and country. As a sensitivity analysis, 
the primary outcome was also analysed unadjusted and as a binary outcome (mRS>3 vs 
mRS≤3). The heterogeneity of the treatment effect on the primary outcome was assessed in 
pre-specified sub-groups and by adding an interaction term into the adjusted ordinal logistic 
regression model. 
 
For secondary outcomes, binary logistic regression (BLR) will be used for binary outcomes, 
including death, SAEs and thromboembolic events. Multiple linear regression (MLR) will be 
used for continuous measures, including haematoma expansion. Wilcoxon rank sum test will 
be used for continuous measures which are not normally distributed, including Barthel Index. 
Cox proportional hazards regression (CPHR) will be used for time to event analyses, 
including death. All regression analyses will be performed with adjustment for stratification 
and minimisation factors, as stated above. To review the overall trend of the data a global test 
(Wei-Lachin) was used on a combination of outcome measures. The impact of tranexamic 
acid on quality of life was assessed using the EuroQoL measure. Comparisons between the 
treatments will be performed in pre-specified subgroups, the low risk groups are given first in 
the brackets, as follows;  
minimisation criteria; computed tomography angiography, CTA (yes, no); Haematoma 
location (deep, lobar) and ethnicity (other, white).  
 
The subgroup analysis did not comprise the primary analysis and thus has not informed the 
sample size calculation. The interpretation of any subgroup effect was based on interaction 
tests (i.e. evidence of differential treatment effects in the different subgroups) and there was 
no adjustment for multiple testing. The minimisation criteria were chosen and included in the 
subgroup analysis as they are independent prognostic indicators of ICH.  
The nominal level of significance for all analyses was p<0.05. No adjustment was made for 
multiplicity of testing. 
 
7.17 Sample size 
The null hypothesis (H0) is that tranexamic acid does not alter death or dependency in 
participants with acute PICH. The alternative hypothesis (HA) is that death or dependency differ 
between those participants randomised to tranexamic acid versus saline. A total sample size of 
2,000 (1,000 per group) participants with acute primary intracerebral haemorrhage are 
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required, assuming overall significance (alpha) = 0.05; power (1-beta) = 0.90; distribution in 
mRS (mRS 0=4%, 1=17% 2=16% 3=19% 4=24% 5=7% 6(death)=13% based on data from 
participants with primary intracerebral haemorrhage in the ENOS trial); ordinal odds ratio of 
0.79; increases due to losses to follow-up of 5%; and a reduction of 20% for baseline covariate 
adjustment.47 In summary, a trial of 2,000 participants (1,700 from main phase and 300 from 
start-up phase) will have 90% power to detect an ordinal shift of mRS outcome with odds ratio 
0.79. 
 
7.18 Protecting against bias, including blinding 
Numerous steps were taken to protect against bias in this double blind RCT, with allocation 
concealment from all staff throughout the study. 
 
7.19 Neuroimaging and scan adjudication 
Brain imaging by CT was done as part of routine care before enrolment; a second research 
CT scan was done after 24 h of treatment to assess haematoma expansion. When multiple 
scans were done, the scan closest to 24 h after randomisation was used. Central independent 
expert assessors, who were masked to treatment assignment, assessed CT scans for the 
location of the intracerebral haemorrhage using a web-based adjudication system. Semi-
automated segmentation of the intracerebral haemorrhage was done on Digital Imaging and 
Communications in Medicine-compliant images to give intracerebral haemorrhage volumes. 
The user-guided three-dimensional active contour tool in the ITK-SNAP software (version 
3.6) was used for segmentation and one of three assessors did manual editing as required. All 
assessments were masked to treatment assignment. 
 
Haematoma expansion was defined as an absolute increase of more than 6 mL or a relative 
growth of greater than 33%. 
 
7.20 Sites, investigators and monitoring 
Investigators were trained in trial procedures via a site initiation teleconference after 
obtaining all of the necessary regulatory approvals. New investigators who joined the study 
after the site initiation training were required to complete and pass an on-line training test 
covering the trial protocol. Monitoring of trial data included confirmation of informed 
consent in all participants; source data verification; data storage and data transfer procedures; 
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local quality control checks and procedures, back-up and disaster recovery of any local 
databases and validation of data manipulation. The Trial Coordinator carried out monitoring 
of trial data throughout the study; entries on case report forms were verified by inspection 
against the source data. A sample of case report forms (10% as per the trial risk assessment) 
were checked for verification of all entries made. In addition, the subsequent capture of the 
data on the trial database was checked. Where corrections were required a full audit trail and 
justification was documented. 
 
7.21 Protocol amendments 
During the course of the trial we had a number of amendments to the study protocol which 
are detailed below. In summary these were to add a number of sub-studies (day 365 follow-
up, MRI sub study and biomarker sub-study) make minor changes to trial documentation and 
allow co-enrolment to the ongoing RCT Re-START. Full details of protocol amendments can 
be found in Appendix 1. 
 
7.22 Sub-studies  
Three sub studies were performed and will be presented elsewhere. Firstly, we performed an 
additional follow up at day 365 and secondly, we performed an MRI sub-study (funded by 
BHF) which will be presented separately. Finally, a single centre plasma biomarker sub-study 
examined effect of tranexamic acid on markers of haemostasis and inflammation. 
 
7.23 Meta-analysis  
In due course data from TICH-2 will be added to summary and individual patient data meta-
analyses in acute stroke. This will include Cochrane,24 and individual patient data meta-
analysis of all tranexamic acid in ICH with the Antifibrinolytics Trialists Collaboration.48 
 
8 RESULTS 
 
8.1 Recruitment 
Recruitment started on 1st March 2013 and ended on 30th September 2017, after a 12-month 
extension was sought and approved to enable the trial to reach its target sample size. This 
slower-than-planned recruitment was due to delays in opening trial sites outside the UK. 
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Subsequently recruitment increased, and the Trial Steering Committee agreed the study 
should exceed the target of 2,000 and continue to the end of the extension. Therefore, a total 
of 2,325 participants (1,161 randomised to TXA and 1,164 to placebo) were recruited from 
124 sites in 12 countries over 55 months (Table 1, Figure 1, 2, 3).  
 
Table 1 Recruitment summary 
Date recruitment started 14 MAR 2013 
Date recruitment stopped 30 SEP 2017 
Number of patients randomised 2325 
Number of centres who have randomised patients 124 
Number of countries who have randomised patients 12 
 
 
Figure 1 Recruitment graph 
 
 
0
500
1000
1500
2000
2500
Jan-13 Aug-13 Mar-14 Sep-14 Apr-15 Oct-15 May-16 Nov-16 Jun-17 Dec-17
N
u
m
b
er
 o
f 
p
ar
ti
ci
p
an
ts
Date
Target Original prediction Recruitment
 36 
 
Table 2 Recruitment by country 
Country 
Participants Randomised 
N (%) 
Average 
per month 
Total number recruited 2325  
United Kingdom 1910 (82.2%) 32.93 
Georgia 141 (6.1%) 3.28 
Italy 96 (4.1%) 1.92 
Malaysia 46 (2.0%) 1.64 
Switzerland 46 (2.0%) 1.53 
Denmark 39 (1.7%) 2.17 
Republic of Ireland 17 (0.7%) 0.65 
Hungary 9 (0.4%) 0.64 
Turkey 9 (0.4%) 0.33 
Sweden 8 (0.3%) 0.29 
Poland 3 (0.1%) 0.19 
Spain 1 (0.0%) 0.06 
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Figure 2 Recruitment by centre 
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Figure 3 Participant flow Consort diagram 
 
 
 
 
8.2 Baseline data 
The majority of participants were recruited in the UK (1910, 82.2%). The mean age was 68.9 
years (SD: 13.8); 1,301 participants (56%) were male. The median time from stroke onset to 
randomisation was 3.6 hours [IQR: 2.6, 5.0] and a third of participants (833, 36%) were 
recruited within 3 hours (Table 3). Mean baseline blood pressure was 173/93 mmHg. The 
majority of participants had a haematoma that was deep and supra-tentorial (1371, 59.0%), 
with 738 (31.7%) lobar supra-tentorial, and a third had IVH. Mean haematoma volume (HV) 
was 24.0 mL (SD: 27.2), median HV 14.1 [IQR 5.9, 32.4]. Contrast enhanced imaging as 
CTA was performed in 249 (10.9%) of participants. 24/121 (19.8%) in the TXA group and 
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32/128 (25%) in the placebo group were spot positive. Treatment groups were well balanced 
at baseline. 
 
Table 3 Clinical characteristics at randomisation 
Baseline variable n TXA Control 
Patients randomised  1161 1164 
Age (years)  2325 69.1 (13.7) 68.7 (13.9) 
Sex, male (%) 2325 642 (55.30%) 659 (56.62%) 
Ethnic origin    
...White (%) 2324 986 (85.00%) 992 (85.22%) 
...Black (%) 2324 49 (4.22%) 47 (4.04%) 
...Asian (%) 2324 107 (9.20%) 111 (9.53%) 
...Other (%) 2324 18 (1.55%) 14 (1.20%) 
Country -UK 2325 954 (82.17%) 956 (82.13%) 
Onset to randomisation (hours) 2325 3.6 [2.6, 5.1] 3.7 [2.6, 5.0] 
History of antiplatelet therapy (%)  2324 316 (27.24%) 295 (25.34%) 
History of statin use (%)   2307 319 (27.69%) 303 (26.23%) 
History of previous stroke or TIA (%) 2301 174 (15.17%) 156 (13.52%) 
History of IHD (%) 2298 110 (9.62%) 92 (7.97%) 
History of thromboembolism (%) 2296 15 (1.31%) 19 (1.65%) 
History of hypertension (%) 2310 700 (60.66%) 721 (62.37%) 
Pre-stroke mRS  2325 0.0 [0.0, 1.0] 0.0 [0.0, 1.0] 
..Pre-stroke mRS>2 (%) 2325 104 (8.96%) 103 (8.85%) 
Glasgow coma scale  2325 13.4 (2.2) 13.5 (2.1) 
NIHSS score 2325 13.1 (7.5) 12.9 (7.5) 
Systolic blood pressure 2325 171.7 (27.5) 173.5 (26.8) 
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Baseline variable n TXA Control 
...>170mmHg (%) 2325 571 (49.18%) 602 (51.72%) 
Diastolic blood pressure 2325 92.9 (18.4) 93.6 (17.8) 
Advanced imaging performed (%) 2277 121 (10.60%) 128 (11.28%) 
...Spot positive  249 24 (19.83%) 32 (25.00%) 
...Spot negative  249 97 (80.17%) 96 (75.00%) 
Haematoma location (%)    
...Supra-tentorial Lobar 2325 379 (32.64%) 359 (30.84%) 
...Supra-tentorial Deep 2325 675 (58.14%) 696 (59.79%) 
...Infra-tentorial 2325 73 (6.29%) 76 (6.53%) 
...Combination 2325 34 (2.93%) 33 (2.84%) 
Haematoma characteristics: l    
Intra-ventricular haemorrhage (%) 2325 382 (32.90%) 363 (31.19%) 
Intracerebral haematoma  
volume (ml) 
2273 24.7 (27.9) 23.3 (26.4) 
Data are number (%), mean (standard deviation, SD), median [interquartile range, IQR] 
 
8.3 Adherence / TXA treatment 
Adherence to the allocated treatment was high: 2,207 (94.9%) participants received all of 
their randomised treatment while only 15 (0.6%) received no treatment; there was no 
difference in adherence rates between the groups. The median time from randomisation to 
treatment was 21 minutes [IQR 13, 33] (Table 4).  
 
 
Table 4 Adherence to study medication 
 TXA Placebo p 
Number of participants randomised 1161 1164  
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    All treatment received  1101 (94.8%) 1106 (95.0%) 0.96 
    Some treatment received 49 (4.2%) 51 (4.4%) 0.66 
   No treatment received 9 (0.8%) 6 (0.5%) 0.48 
   Not known  2 (0.2%) 1 (0.1%) 0.54 
Incorrect drug administration* 31 (2.7%) 26 (2.2%) 0.56 
Time until first dose (minutes) 21 [13, 33]  21 [13, 32]  0.49 
*Protocol violations were investigator reported. Data are number (%), median [IQR]. 
 
8.4 Time to treatment  
Median time [IQR] for stroke onset to randomisation was 3.6 hours [2.6, 5.0] (figure 4), with 
827 (35.6%) participants enrolled within 3 hours and 1571 (67.6%) participants enrolled 
within 4.5 hours. Median time to CT scan  was 1.9 hours  [1.4, 2.9]; 77% of participants had 
a CT scan within 3 hours of symptom onset, and 93% within 4.5 hours (figure 5). Median 
time from CT scan to randomisation was 1.3 hours  [0.8, 2.1] figure 6. with 861 (37%) 
participants randomised within 1 hour of CT scan  and 1681 (72.3%) participants 
randomised within 2 hours of CT scan  . The majority of participants took more than 1 hour 
to enrol after CT scan was performed. The median time to first dose was 4.1 hours after 
stroke onset (figure 7), 25% of participants were treated within 3 hours of stroke onset and 
58% within 4.5 hours. 
 
 
 
 
 
 
 
 
 
 
 
 
 42 
 
 
 
 
Figure 4 Time from stroke onset to randomisation 
 
 
 
Figure 5 Time from stroke onset to CT scan 
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Figure 6 Time from CT scan to randomisation 
 
 
Figure 7 Time from stroke onset to treatment 
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8.5 Consent 
The majority of participants were enrolled after consent by a relative (Table 5). Participants 
with more severe stroke (higher NIHSS) were more likely to use relative or doctor consent. 
Independent doctor consent had the shortest time from onset to randomisation (3.25 hours) 
compared to full informed consent from a relative which took the longest (4.21 hours). 
 
Table 5 Consent type utilised 
Consent type N 
NIHSS 
mean 
Time (OTR) 
mean 
Patients with data 2325 13 3.94 
Fully informed participant 558 (24.0%) 7.58 3.97 
Brief participant 260 (11.2%) 9.03 3.59 
Fully informed relative 996 (42.8%) 15.1 4.21 
Brief relative 323 (13.9%) 16.1 3.75 
Doctor 188 (8.1%) 18 3.25 
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OTR onset to randomisation time 
 
8.6 Primary efficacy outcome 
The primary outcome of mRS at day 90 was determined in 2,307 (99.2%) participants; 9 
(0.4%) were lost to follow-up and 9 (0.4%) withdrew from their day 90 follow-up (figure 3). 
There was no difference in the distribution (shift) in the mRS at day 90 after adjustment for 
stratification and minimisation criteria, adjusted odds ratio (aOR) 0.88 (95% CI 0.76 to 1.03), 
p=0.11 (figure 8). A formal goodness-of-fit test gave no evidence that the proportional odds 
assumption was violated (p=0.97). There was no difference between the TXA and placebo 
groups in the proportion of participants who were dead or dependent (mRS >3), aOR 0.82 
(95% CI 0.65 to 1.03), p=0.08. 
 
Figure 8 Primary outcome -shift plot of Day 90 mRS 
 
mRS level descriptions:  
0 – No symptoms  
1 – No disability despite symptoms  
2 – Slight disability but able to look after own affairs 
3 – Moderate disability but able to walk without assistance 
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4 – Moderately severe disability; unable to walk or attend to own bodily needs  
5 – Severely disabled; bedridden and requiring constant nursing care 
6 – Death  
Adjusted odds ratio 0.88, 95% CI (0.76, 1.03), p-value=0.11 
Figure 8 is reproduced from the Lancet article "Tranexamic acid for hyperacute primary 
IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 
superiority trial" https://doi.org/10.1016/S0140-6736(18)31033-X 
 
 
8.7 Sub-group analysis:  
When the primary outcome was assessed in pre-specified subgroups (figure 9), the only 
significant interaction was between mRS and baseline systolic blood pressure (interaction 
p=0.016) such that participants with a baseline systolic blood pressure <170 mmHg had a 
favourable shift in mRS with TXA as compared to those with a systolic blood pressure ≥170 
mmHg. There was no heterogeneity of treatment effect by time to enrolment (Figure 9) 
whether dichotomised at <3 hours vs. 3 hours (interaction p=0.89) or ≤4.5 hours vs. >4.5 
hours (interaction p=0.28); similarly, there was no interaction between treatment effect and 
time when analysed as a continuous variable (aOR 0.98 [95%CI 0.90 to 1.07, p=0.69). 
In exploratory post hoc analysis, participants with moderate haematoma size 30-60mls have a 
favourable shift in mRS with TXA aOR 0.66 (0.44 to 0.98, p=0.039) but the interaction 
between haematoma size and treatment was not statistically significant (p=0.84). This 
difference was statistically significant when studying the 1350 participants with a haematoma 
size of <=60mls who were enrolled within 4.5 hours of onset aOR 0.821 (0.67-0.98, 
p=0.031). However, the interaction between haematoma size and treatment in patients 
randomised within 4.5 hours was not statistically significant (p=0.55).   
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Figure 9 Forest plot of Day 90 mRS in subgroups. Haematoma volume was not pre-specified 
and was an exploratory post-hoc analysis. 
 
8.8 Secondary outcomes:  
Radiological outcomes: There were fewer participants with haematoma expansion at day 2 in 
the TXA group (265, 25.1%) as compared to placebo (304, 28.7%) (aOR 0.80, 95% CI 0.66 
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to 0.98, p=0.030) table 6. The mean increase in haematoma volume from baseline to 24 hours 
was also less in the TXA group (3.72ml, SD 15.9) compared to placebo (4.90ml, SD 16.0) 
(aMD -1.37, 95% CI -2.71 to -0.04; p=0.043).  
Clinical outcomes: Neurological impairment (mean NIHSS score at day 7) did not differ 
between the TXA group (10.1) and placebo group (10.3) (aMD -0.43, 95% CI -0.94 to 0.09; 
p=0.10) table 6.  
 
Table 6 Radiological outcomes and early clinical outcomes 
 
 
N TXA Placebo 
OR/MD  
(95% CI) p 
Radiological outcomes:      
Change in volume from baseline 
to 24 hours* 
2112 3.72 (15.9) 4.90 (16.0) MD: -1.37 (-2.71 
to -0.04) 
0.043 
Participants with haematoma 
expansion† 
2112 265 
(25.1%) 
304 
(28.7%) 
Binary OR: 0.80 
(0.66 to 0.98) 
0.030 
Clinical outcomes day 7      
Death by day 7 2325 101 (8.7%) 123 
(10.6%) 
Binary OR: 0.73 
(0.50 to 0.99) 
0.041 
NIHSS day 7  1829 
10.13 (8.3) 10.29 (8.3) 
MD: -0.43 (-0.94 
to 0.09) 
0.10 
* Adjusted for baseline haematoma volume; † haematoma expansion defined as an increase 
of >6l or a growth of >33%. 
 
Clinical outcomes day 90: There were no significant differences in any of the day 90 
functional outcomes between treatment groups: activities of daily living (BI), mood (ZDS), 
cognition (TICS-M, verbal fluency), or quality of life (EQ-5D HUS, EQ-VAS; table 7. 
Cost outcomes: Length of hospital stay and discharge disposition did not differ between 
treatment groups (table 7). 
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Table 7 Day 90 secondary outcomes 
 
 
N TXA Placebo 
OR/MD  
(95% CI) p 
Death by day 90 2325 250 
(21.5%) 
249 
(21.4%) 
HR: 0.92  
(0.77 to 1.10) 
0.37 
EQ-5D HUS day 90 2244 0.34 (0.4) 0.34 (0.4) MD: 0.01  
(-0.01 to 0.04) 
0.30 
EQ-VAS day 90 2081 48.81 
(33.8) 
48.34 
(33.1) 
MD: 1.75  
(-0.52 to 4.02) 
0.13 
Barthel Index day 90 2231 52.92 
(44.0) 
53.21 
(43.7) 
MD: 1.70  
(-0.90 to 4.31) 
0.20 
TICS-M day 90 1216 13.57 
(12.5) 
13.94 
(12.8) 
MD: -0.19  
(-1.12 to 0.74) 
0.69 
ZDS day 90 1319 67.28 
(29.5) 
67.29 
(29.9) 
MD: -0.35  
(-2.60 to 1.90) 
0.76 
Global analysis (Wei-Lachin 
test) day 90 
2307   MWD: 0.00  
(-0.05 to 0.04) 
0.85 
Length of stay in hospital 
(days) 
2312 63.12 
(47.1) 
63.73 
(48.1) 
MD: 1.09  
(0.97 to 1.24) 
0.16 
If discharged, days well at 
home 
1007 69.94 
(28.6) 
72.15 
(29.1) 
MD: -0.72  
(-3.73 to 2.28) 
0.64 
Home discharge 2325 465 
(40.1%) 
453 
(38.9%) 
Binary OR: 1.14 (0.93 to 
1.40) 
0.20 
Institutionalisation 2325 505 
(43.5%) 
506 
(43.5%) 
Binary OR: 0.99 (0.83 to 
1.18) 
0.90 
Died by discharge 2325 190 
(16.4%) 
205 
(17.6%) 
Binary OR: 0.83 (0.65 to 
1.07) 
0.15 
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8.9 Process of care measures 
The majority of participants received intravenous blood pressure lowering treatment (75.3% 
in the TXA group and 74.5% in the placebo group) on the first day. By day 7 nearly all 
participants had received blood pressure lowering treatment (81.6% in the TXA group and 
83.5% in the placebo group).  
 
The use of Do Not Attempt Resuscitation (DNAR) orders increased from 17% in the first 24 
hours, to 22% by day 7, but there was no difference between the treatment groups (Table 8).  
Only 5% of participants underwent neurosurgery, with similar rates within both treatment 
groups. 10% of participants were transferred to intensive care units, with 7% of participants 
undergoing ventilation. Rates of ITU transfer and ventilation did not differ between the 
treatment groups. 
 
Table 8 Process of care measures at Day 2 and Day 7 
 N TXA Placebo All P  
Day 2 2325 1161 1164 2325   
BP treatment 2325 851 (73.3%) 886 (76.1%) 1737(74.7%) 0.39  
-  BP route (IV) 1737 641 (75.3%) 660 (74.5%) 1301(74.9%) 0.78  
Do Not Attempt Resuscitation 2325 193 (16.6%) 199 (17.1%) 392 (16.9%) 0.26  
       
Day 7 2325 1161 1164 2325   
BP treatment 2325 947 (81.6%) 972 (83.5%) 1919(82.5%) 0.59  
-  BP route (IV) 1919 545 (57.6%) 585 (60.2%) 1130(58.9%) 0.21  
Do Not Attempt Resuscitation 2325 255 (22.0%) 254 (21.8%) 509 (21.9%) 0.59  
Neurosurgery received 2325 57 (4.9%) 64 (5.5%) 121 (5.2%) 0.60  
Intensive care unit transfer 2325 113 (9.7%) 119 (10.2%) 232 (10.0%) 0.84  
Invasive ventilation 2325 82 (7.1%) 84 (7.2%) 166 (7.1%) 0.92  
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8.10 Safety outcomes 
There were fewer deaths by day 7 in the TXA group (101, 8.7%) compared to the placebo 
group (123, 10.6%), (aOR 0.73, 95% CI 0.53 to 0.99, p=0.041).  
The numbers of deaths by day 90 did not differ between the TXA group (250/1161, 21.5%) 
and the placebo group (249/1164, 21.4%; table 7). There was no difference in survival was 
seen between treatment groups over 90 days (adjusted hazard ratio 0.92, 95% CI 0.77 to 1.10, 
p =0.37 (figure 10).  
 
Figure 10 Plot of cumulative mortality  
 
8.11 Serious adverse events 
A total of 1599 events were reported as serious adverse events, of which 1355 were serious 
adverse events and 200 serious adverse reactions (figure 11). There were no suspected 
unexpected serious adverse reactions (table 9). 
 
Fewer participants experienced safety outcomes and serious adverse events day 2 (32.6% vs. 
35.8%), 7 (39.3% vs. 42.7%) and 90 days (44.9% vs.47.8%) were significantly lower in the 
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TXA group (table 9). There was no increase in venous thromboembolic events (3.4% in the 
TXA group vs. 3.2% in the placebo group; p=0.98), or arterial occlusions (myocardial 
infarction, acute coronary syndrome, or peripheral arterial occlusion) in the TXA group (table 
9). 
 
Seizure was the most common safety outcome but there was no difference between the 
groups (77 [7%] patients in the tranexamic acid group vs 85 [7%] in the placebo group). 
Nervous system disorders were the most common serious adverse events (149 [13%] vs 163 
[14%]), followed by infections (98 [8%] vs 116 [10%]). 
 
Figure 11 Serious adverse events reported by investigators 
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Table 9 Serious adverse events/reactions  
 
Median days to 
event 
TXA 
1161 
Placebo 
1164 p 
By day 2  379 (32.6%) 417 (35.8%) 0.027 
By day 7  456 (39.3%) 497 (42.7%) 0.020 
By day 90   521 (44.9%) 556 (47.8%) 0.039 
     
By Classification     
SAE 1 [0, 3] 493 (42.5%) 517 (44.4%) 0.11 
SAR 2 [1, 4] 92 (7.9%) 95 (8.2%) 0.69 
     
Safety outcomes     
Death 1 [0, 15] 250 (21.5%) 249 (21.4%) 0.60 
ACS or MI 5 [1, 53] 11 (0.9%) 6 (0.5%) 0.24 
Deep vein thrombosis 
(DVT) 
15 [10, 34] 19 (1.6%) 14 (1.2%) 0.41 
Pulmonary embolism (PE) 16 [8, 29] 20 (1.7%) 23 (2.0%) 0.58 
VTE (combined DVT/PE) 16 [10, 30] 39 (3.4%) 37 (3.2%) 0.98 
Seizure / convulsions 1 [0, 3] 77 (6.6%) 85 (7.3%) 0.44 
Ischaemic stroke or TIA 9 [2, 52] 16 (1.4%) 11 (0.9%) 0.27 
     
SAEs by subcategory     
Blood and lymphatic system 
disorders 
0 [0, 4] 1 (0.1%) 2 (0.2%) 0.41 
Cardiac disorders 1 [1, 2] 14 (1.2%) 10 (0.9%) 0.48 
Gastrointestinal disorders 1 [0, 2] 12 (1.0%) 9 (0.8%) 0.59 
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Median days to 
event 
TXA 
1161 
Placebo 
1164 p 
General disorders and 
administration site 
conditions 
2 [1, 3] 2 (0.2%) 2 (0.2%) 0.95 
Immune system disorders 0 [0, 1] 1 (0.1%) 2 (0.2%) 0.51 
Infections and infestations 2 [1, 3] 98 (8.4%) 116 (10.0%) 0.14 
Injury, poisoning and 
procedural complications 
1 [1, 3] 7 (0.6%) 10 (0.9%) 0.53 
Metabolism and nutrition 
disorders 
4 [1, 7] 0 2 (0.2%) 0.99 
Musculoskeletal and 
connective tissue disorders 
1 [1, 1] 0 1 (0.1%) 0.99 
Neoplasms benign, 
malignant and unspecified 
4 [1, 5] 3 (0.3%) 3 (0.3%) 0.89 
Nervous system disorders 1 [0, 1] 171 (14.7%) 189 (16.2%) 0.24 
Psychiatric disorders 4 [3, 5] 1 (0.1%) 4 (0.3%) 0.26 
Renal and urinary disorders 2 [1, 4] 14 (1.2%) 17 (1.5%) 0.66 
Respiratory, thoracic and 
mediastinal disorders 
1 [1, 2] 4 (0.3%) 3 (0.3%) 0.72 
Skin and subcutaneous 
tissue disorders 
5 [5, 5] 2 (0.2%) 0 0.99 
Vascular disorders 1 [0, 2] 7 (0.6%) 9 (0.8%) 0.64 
Miscellaneous 1 [0, 3] 7 (0.6%) 6 (0.5%) 0.81 
Data are number (%), median [IQR]. This table gives details on the serious adverse events 
experienced up until each participant’s day 7 follow-up; safety outcomes and death are 
collected up until day 90. The numbers given in each group are per participant, as opposed to 
the total number of events.  
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8.12 Protocol violations 
A total of 331 protocol violations we reported by investigators, with 87 meeting the protocol 
definition of a protocol violation (table 10). The commonest protocol violation was failure of 
participant to receive all of the allocated treatment, which occurred in 1% of participants. 
 
Table 10  Protocol violations by category 
Protocol Violation 
TXA 
N (%) 
Placebo 
N (%) 
All 
N (%) 
Patients with data 1161 1164 2325 
Number of protocol violations entered by 
investigators 
164 167 331 
Number adjudicated to not be a protocol violation 129 115 244 
Number of protocol violations 35 52 87 
Baseline characteristics    
Randomisation over 8 hours from onset of 
symptoms 
1 (0.1%) 0 1 (0.0%) 
Baseline cranial imaging shows underlying 
structural abnormality, e.g. tumour or arterial 
venous malformation 
1 (0.1%) 2 (0.2%) 3 (0.1%) 
On anticoagulation 0 1 (0.1%) 1 (0.0%) 
Randomising event was secondary to trauma 1 (0.1%) 0 1 (0.0%) 
Not a primary intracerebral haemorrhage 1 (0.1%) 1 (0.1%) 2 (0.1%) 
Practice during the trial    
Subsequent randomisation into another drug of 
devices trial 
1 (0.1%) 0 1 (0.0%) 
Participant does not receive all of the randomised 
treatment 
13 (1.1%) 15 (1.3%) 28 (1.2%) 
Consent and re-consent    
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Protocol Violation 
TXA 
N (%) 
Placebo 
N (%) 
All 
N (%) 
Failure to obtain any consent - neither brief 
information sheet/assent nor fully informed 
consent 
0 3 (0.3%) 3 (0.1%) 
Failure to obtain appropriate, fully informed 
consent (following brief or independent physician 
consent) 
0 5 (0.4%) 5 (0.2%) 
Individual taking consent not authorised to take 
consent on delegation log 
2 (0.2%) 5 (0.4%) 7 (0.3%) 
Wrong consent form used to obtain fully informed 
consent 
2 (0.2%) 4 (0.3%) 6 (0.3%) 
Follow-up assessments performed    
Day 2 follow-up - over 2 days past due date 1 (0.1%) 1 (0.1%) 2 (0.1%) 
Day 7 follow-up - over 7 days past due date 2 (0.2%) 1 (0.1%) 3 (0.1%) 
Day 90 follow-up - over 30 days past the due date 2 (0.2%) 6 (0.5%) 8 (0.3%) 
Miscellaneous    
Any other major deviation from the trial protocol 8 (0.7%) 8 (0.7%) 16 (0.7%) 
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9 DISCUSSION AND CONCLUSION 
 
9.1 Interpretation 
In this international multi-centre randomised controlled trial of tranexamic acid after acute 
intracerebral haemorrhage, there was no statistically significant difference in the primary 
outcome of functional status at day 90. Despite no significant improvement in primary 
outcome there were statistically significant yet modest reductions in the pre-specified 
secondary outcomes of early death, haematoma expansion and serious adverse events. There 
was no increase in thromboembolic events or seizures. 
 
In keeping with an antifibrinolytic effect, tranexamic acid was associated with a modest yet 
statistically significant reduction in haematoma expansion and smaller growth in haematoma 
volumes, key factors known to influence outcome after intracerebral haemorrhage. However, 
the small reduction in haematoma volume growth (1.4ml), and proportion of participants 
experiencing haematoma expansion (29% in the placebo group compared to 25% in the TXA 
group) may have been too small to translate into improved functional status in this 
population.  
 
Therefore, whilst it is possible that tranexamic acid is not effective at improving outcome 
after ICH, an alternative explanation for our findings is that the observed treatment effect was 
too modest. Our sample size calculation was based on an estimated effect size of OR 0.79 
which the trial did not detect. The observed OR was 0.88 and a much larger sample size 
would be required to detect this. Indeed previous randomised controlled trials of tranexamic 
acid in other settings have randomised tenfold the number of participants to identify more 
modest effects on bleeding-related deaths after trauma (OR 0.85)22 and post-partum 
haemorrhage (OR 0.81).12 Furthermore, an individual patient data meta-analysis of two RCTs 
(with >40,000 participants), published after enrolment in TICH-2 had completed, has 
subsequently confirmed that commencing tranexamic acid within 3 hours of start of bleeding 
is necessary for benefit of tranexamic acid after trauma or post-partum haemorrhage.14 
Despite repeated efforts to encourage investigators to reduce time to enrolment, the majority 
of our participants were enrolled after 3 hours. Recent meta-analysis of individual patient 
data in 5435 patients has demonstrated that the probability of haemorrhage growth declines 
mostly steeply 3 hours after symptom onset,49 highlighting the need for urgent treatment.  
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In the same meta-analysis, baseline haematoma volume was the strongest predictor of 
outcome after spontaneous intracerebral haemorrhage. The probability of haematoma growth 
increased with baseline haematoma volume, but peaked at 75mls.49 In TICH-2, in an 
exploratory post hoc analysis, participants with a baseline haematoma volume of between 30 
and 60mls who received tranexamic acid appeared to have better outcome (aOR 0.66 (0.44 to 
0.98, p=0.039, Figure 9)), but the interaction between haematoma volume and treatment was 
not significant (p=0.84). Although this could be due to chance and caution is needed when 
interpreting sub-groups, it is also compatible with the hypothesis that patients with moderate 
size haematomas may be more likely to benefit from haemostatic therapies, and hence could 
be targeted for future studies, as has been postulated with recombinant factor VIIa.23,22  
 
The statistically significant interaction demonstrated here between baseline systolic blood 
pressure and treatment suggests participants with lower blood pressure were more likely to 
benefit from tranexamic acid. This finding could have been confounded by stroke severity, as 
larger haematomas have increased blood pressure and worse outcomes.21,25 Despite being the 
only intervention to date to improve functional outcome after intracerebral haemorrhage, 
early intensive blood pressure lowering2 remains controversial.10 Whilst there were no 
significant effects on haematoma growth in INTERACT-2,2 secondary analysis suggested 
blood pressure lowering did attenuate bleeding in a dose-dependent manner.24 The interaction 
demonstrated here between systolic blood pressure and tranexamic acid suggests 
complimentary approaches to reduce haematoma expansion, with haemostatic and 
haemodynamic therapies warrants further investigation.  
 
Unlike other acute ICH studies with recombinant factor VIIa23 and aggressive lowering 
blood-pressure,9 we found no evidence of adverse effects. Notably there was no increase in 
venous thromboembolism or seizures in this significantly older population with more co-
morbidities than participants in previous studies of tranexamic acid. 22,12 It is therefore 
unlikely that any potential benefit of tranexamic acid was offset by harm, as has been 
suggested with recombinant factor VIIa.23 In a phase III trial, there was no evidence of 
clinical benefit of recombinant factor VIIa, with a reduction in haematoma expansion but an 
increased risk in arterial occlusive events.23 Whilst tranexamic acid and recombinant factor 
VIIa are both haemostatic agents, tranexamic acid has antifibrinolytic mechanisms and 
recombinant factor VIIa is a pro-coagulant, and hence they have different risk-benefit 
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profiles. Recent studies with recombinant factor VIIa have attempted to use the spot sign to 
identify those at risk of haematoma expansion and as such most likely to benefit from 
rFVIIa.25, 26 However, the trials were stopped due to poor recruitment.27 We have also 
demonstrated here that selecting large numbers of patients based on the spot sign is not 
practicable as only 10% of participants had advanced imaging performed. Whilst the 
presence of spot sign does improve prediction of ICH growth; time from onset, 
antithrombotic therapy and baseline haematoma volume remain the strongest predictors.49 
 
9.2 Generalisability 
Our inclusion criteria were deliberately broad, with recruitment from international sites, 
across secondary and tertiary care, reflective of the clinical population. However, we were 
unable to collect screening logs across such a large number of sites and as such are unable to 
determine the proportion of population who would be eligible for haemostatic therapy if it 
were effective.  
 
9.3 Overall evidence 
In systematic review,24 we found 2 small randomised controlled trials of TXA with a total of 
54 participants, with no clear evidence of benefit or harm associated with tranexamic acid.37, 
38 Several smaller randomised controlled trials of tranexamic acid in intracerebral 
haemorrhage are on-going,50-54 with a total enrolment of less than 1000 participants across all 
the trials. A number of these on-going trials are targeting participants likely to be at greater 
risk of haematoma expansion, earlier time window50, 51 spot sign status,51, 54 and 
anticoagulation.55 Whilst an individual patient data meta-analysis is planned32 further large 
randomised trials are needed to confirm or refute a clinically significant treatment effect of 
tranexamic acid. 
 
9.4 Strengths 
The strengths of this study include double-blinding and strong allocation concealment, with 
low risk of bias, high adherence to treatment and high completion of follow up with very few 
missing primary outcomes. Use of approved brief (see supplementary data) and proxy 
consent processes allowed rapid enrolment of patients without capacity, important in acute 
stroke studies. Independent doctor consent was the most rapid form of consent and maybe 
appropriate in emergency studies, when relatives struggle to make informed decisions.  
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Minimisation techniques were effective and the treatment groups were well matched at 
baseline. The sample size was large, making this the largest haemostatic therapy RCT after 
ICH. Pre-study support from the Nottingham Clinical Trials Unit ensured that approvals were 
obtained rapidly once the grant was activated, allowing recruitment to begin in a timely 
manner. This rapid set up process led to a large number of sites being activated ahead of 
schedule, with recruitment in the UK exceeding initial expectations, which lead to early 
achievement of the stop-go criteria. The large number of sites participating in the UK would 
not have been possible without the support of the NIHR CRN in England and adoption of 
TICH-2 on the study portfolio. The absence of an effective drug therapy for ICH, in 
combination with streamlined processes of acute stroke care to facilitate reperfusion therapies 
in ischaemic stroke and absence of competing trials lead to TICH-2 fitting well into the acute 
stroke clinical pathway and ensured good engagement with clinicians. Finally, permission 
was sought and granted to allow co-enrolment into The REstart or STop Antithrombotics 
Randomised Trial (RESTART); an investigator-led, randomised trial comparing starting 
versus avoiding antiplatelet drugs for adults surviving antithrombotic-associated ICH.56 The 
TSCs for both studies felt that co-enrolment did not affect the safety of participants, or the 
quality of the scientific data and yet allowed both important clinical questions to be 
answered, something that the PPI group strongly supported.20 participants were co-enrolled, 
10 in the TXA group, 10 in the control group. 
 
9.5 Limitations 
The wide inclusion criteria inclusive led to a heterogeneous population, with multiple co-
morbidities, more severe strokes, larger haematoma volumes and a greater proportion of 
participants with lobar haematomas and intraventricular haemorrhage as compared to other 
intracerebral haemorrhage trials.2,21,23,26 This inclusion of older participants with more 
comorbidities and larger haematomas in particular could have diluted any treatment effect.  
As already highlighted, the majority of participants were enrolled more than 3 hours after 
ICH onset which could explain the absence of a significant interaction with time in subgroup 
analysis. In 2016 the protocol for the on-going RCT CRASH-3 (testing TXA in traumatic 
brain injury) was amended to reduce the time window for eligibility (originally within 8 
hours of injury) to patients within 3 hours of injury.57 The TSC for TICH-2 discussed on a 
number of occasions whether the inclusion criteria should be amended to limit recruitment to 
participants within 3 hours of symptom onset in line with other TXA studies. However, as the 
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majority of recruitment had been completed, and there are important pathophysiological 
differences between ICH and TBI, the decision was taken to leave the inclusion criteria 
unchanged but to focus on efforts to ensure rapid treatment. Had this been an adaptive trial 
design, enrichment could have allowed further recruitment within subgroups where TXA was 
most likely to be effective, such as those presenting <3 or <4.5 hours, or those with moderate 
sized haematomas. Furthermore, sample size reassessment to account for the fact that the 
observed effect size was lower than predicted in the original sample size calculation, may 
have been beneficial.58  
 
We did not seek to explore mechanistic approaches by which TXA could improve outcome. 
This could be done firstly by addressing how TXA may reduce haematoma expansion, and it 
is thus unclear whether reduction in number of participants experiencing haematoma 
expansion is related to attenuation of primary bleeding, secondary vessel rupture, both or 
neither. More research is needed to understand the time course of changes after acute 
intracerebral haemorrhage and differences between lobar and deep haematomas. Whilst we 
collected data on haematoma location and local investigators assigned a final diagnosis – we 
acknowledge that recognising cerebral amyloid angiopathy (CAA) is a challenge and many of 
the participants, particularly elderly, may have undiagnosed CAA. Further work is currently 
being undertake to analyse participants brain imaging and will be presented at a later date. 
Secondly, beyond antifibrinolytic effects there is increasing recognition that because of its 
inhibition of plasmin, TXA has anti-inflammatory properties. This anti-inflammatory action 
has been speculated to be important for the efficacy of TXA.59 Inflammation is a key 
contributor to secondary brain injury after ICH and the effects of TXA on this warrant further 
investigation. 
 
Although the recruitment process was simple and enrolment could be done by a doctor, the 
majority of participants were enrolled during working hours, due in part to a reliance on 
clinical research network staff. Only a small number of hyperacute stroke research centres in 
the UK have coverage from clinical research network staff in the evenings and at weekends. 
It is therefore likely that a large number of potential participants were not considered for 
enrolment as they presented with stroke symptoms outside of normal working hours. 
Furthermore, requiring the NIHSS to be measured before randomisation reduced the number 
of participants enrolled in the emergency department due to lack of availability of trained 
staff, again particularly out of hours. For this reason, we did not collect haematoma volume at 
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baseline, as measuring haematoma volume is not currently part of standard clinical care in the 
majority of hospitals. It was therefore not possible to minimise on the basis of haematoma 
volume. 
 
Finally, whilst study set up and recruitment in the UK exceeded expectations, set up in 
International sites took longer than expected, with governance issues contributing to 
significant delays. This was the main contributing factor that necessitated the one year 
contract extension in order to allow recruitment targets to be met. This delay in starting the 
study in International Sites meant the majority of participants were recruited from the UK, 
limiting international generalisability. 
 
9.6 Public-patient involvement 
Haemorrhagic stroke was highlighted as a research priority by the Stroke Association and 
stroke survivors have been involved throughout the trial, since the conception of the study. 
Nottingham Stroke Research Partnership, made up of stroke survivors and carers reviewed 
the proposed study, in an iterative process, commented on its design and conduct. In 
particular the group influenced the approach to taking informed consent within the study. The 
group felt strongly that all should be done to allow as many people suffering from stroke to 
take part in the study. In particular they recognised that in the emergency situation of an acute 
stroke it is often impossible to take in information to allow people to fully decide whether 
they wish to take part in the study, due to speech and processing problems caused by the 
acute stroke. In this instance they would want to be included in such a study, unless there was 
a medical reason not to, or if they had pre-expressed a desire not to want to take part. They 
also recognised that many people arrive in hospital alone after a stroke without family 
members present. It was for this reason we sought permission for enrolment after consultation 
with independent physician when no family or friends are present. 
 
Malcom Jarvis and Christine Knott, both stroke survivors were members of the trial steering 
committee throughout the duration of the trial. In addition to shaping the informed consent 
processes, stroke survivors (Nottingham Stroke Research Partnership group) provided advice 
on how best to inform participants of the study results, which included developing a lay 
summary for the trial, which is available on the study website. Malcolm Jarvis and Christine 
Knott helped prepare the primary publication and this report. 
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9.7 Conclusions 
TICH-2 is the first large multi-centre international randomised controlled trial of tranexamic 
acid, in acute spontaneous ICH. There was no statistically significant improvement in 
functional status at 90 days. Significant yet modest reduction in the number of participants 
with haematoma expansion and fewer early deaths in those allocated tranexamic acid are 
consistent with tranexamic acid having an antifibrinolytic effect after ICH. Tranexamic acid 
was safe, with fewer serious adverse events and no increase in thromboembolic events or 
seizures. Pre-specified sub-group analyses suggested that treatment for participants with 
lower blood pressure may be beneficial. Whilst analysis did not demonstrate an interaction 
with time to enrolment, earlier treatment in those with modest haematoma size (excluding 
those with very large haematomas who may have already undergone haematoma expansion) 
may be optimal. 
9.8 Implications for healthcare 
Whilst there is insufficient evidence to support the routine use of tranexamic acid in clinical 
practice for spontaneous intracerebral haemorrhage, the results do not exclude a modest but 
clinically important treatment effect.   
 
Tranexamic acid is affordable, widely available, easier to administer and appears to be safe. 
Even a modest benefit could have a global impact on the excessive burden of mortality and 
morbidity after ICH.  
 
9.9 Recommendations for research 
Although a number of smaller randomised trials are on-going50-54, 60 further large randomised 
trials are likely to be needed to confirm or refute a clinically significant treatment effect. 
Future research should investigate which subgroups of patients may benefit. Enriching future 
trial populations with participants most likely to benefit from haemostatic agents (for 
example those presenting early, with moderate haematomas, excluding participants with pre-
destined poor outcome) may reduce sample size but should not be done at the expense of 
increasing complexity of study design. Focus must primarily be on enrolling participants as 
soon as possible after diagnosis of intracerebral haemorrhage. One on-going  study is already 
seeking enrol participants in the pre-hospital time window.60 Trial design (including 
participant selection and consent processes) need to be streamlined and as fast as possible in 
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this emergency situation. Embedding trials into the clinical pathway is essential to ensure 
adequate recruitment and generalisability of results. Finally, harmonisation of approval 
processes could reduce set-up time and expense needed to complete large international 
studies, thereby reducing research waste.61 
 
10 Acknowledgements 
 
We thank the participants, investigators and research staff at the participating sites and the 
members of the Independent Data Monitoring Committee and Trial Steering Committee, for 
their involvement in and support for, the study.  Philip M Bath and Thompson G Robinson 
are NIHR Senior Investigators. The study could not have been performed in the UK without 
the support of the NIHR CRN and staff in the 84 participating sites.  
Sections of this report are reproduced from the Lancet article "Tranexamic acid for hyperacute 
primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, 
phase 3 superiority trial"  https://doi.org/10.1016/S0140-6736(18)31033-X 
 and is available under the terms of the Creative Commons Attribution License (CC BY) 
https://creativecommons.org/licenses/by/4.0/# 
 
 
11 Contributions 
 
Nikola Sprigg: Chief Investigator, conceived the trial, wrote the first draft of the manuscript, 
critically appraised the manuscript and approved the final version 
 
Katie Flaherty: performed the statistical analysis, critically appraised the manuscript and 
approved the final version. 
 
Jason P Appleton: Trial medic, responsible for the day to day running of the trial, critically 
appraised the manuscript and approved the final version. 
 
Rustam Al-Shahi Salman: Is a member of EME Funding Committee 
 
Daniel Bereczki: National Coordinator in Hungary and critically appraised the manuscript 
and approved the final version. 
 65 
 
Maia Beridze: National Coordinator in Georgia and critically appraised the manuscript and 
approved the final version. 
 
Alfonso Ciccone: National Coordinator in Italy and critically appraised the manuscript and 
approved the final version. 
 
Ronan Collins: National Coordinator in Ireland and critically appraised the manuscript and 
approved the final version. 
 
Michal Karlinski: Lead Investigator in Poland, critically appraised the manuscript and 
approved the final version. 
 
Robert A Dineen: led the adjudication of neuroimaging, critically appraised the manuscript 
and approved the final version. 
 
Lelia Duley: Member of the Trial Steering Committee, critically appraised the manuscript 
and approved the final version. 
  
Juan Jose Egea-Guerrero: National Coordinator in Spain, critically appraised the manuscript 
and approved the final version. 
 
Timothy J England: Lead the adjudication of serious adverse events, critically appraised the 
manuscript and approved the final version. 
 
Kailash Krishnan: Performed radiological measurements (including haematoma volume), 
critically appraised the manuscript and approved the final version. 
 
Ann Charlotte Laska: National Coordinator in Sweden, critically appraised the manuscript 
and approved the final version. 
 
Zhe Kang Law: Trial medic, responsible for the day to day running of the trial, critically 
appraised the manuscript and approved the final version. 
 
 66 
Christian Ovesen: Lead the spot sign subgroup analysis, critically appraised the manuscript 
and approved the final version. 
 
Serefnur Ozturk: National Coordinator in Turkey, critically appraised the manuscript and 
approved the final version. 
 
Stuart J Pocock: Lead statistician, supervised the analysis performed by Katie Flaherty and 
Polly Scutt. 
 
Ian Roberts: Co-applicant and member of Trial Steering Committee, critically appraised the 
manuscript and approved the final version. 
 
Thompson G Robinson: Co-applicant and member of Trial Steering Committee, critically 
appraised the manuscript and approved the final version. 
 
Christine Roffe: Co-applicant and member of Trial Steering Committee, critically appraised 
the manuscript and approved the final version. 
 
Nils Peters: Lead Investigator in Switzerland, critically appraised the manuscript and 
approved the final version. 
 
Polly Scutt: Performed the statistical analysis with supervision, critically appraised the 
manuscript and approved the final version. 
 
Jegan Thanabalan: National Coordinator in Malaysia, critically appraised the manuscript and 
approved the final version. 
 
David Werring: Co-applicant and member of Trial Steering Committee, critically appraised 
the manuscript and approved the final version. 
 
David Whynes: critically appraised the manuscript and approved the final version. 
 
Lisa Woodhouse: Performed some of the statistical analysis critically appraised the 
manuscript and approved the final version. 
 67 
 
 
Philip M Bath: Deputy Chief Investigator, co- conceived the trial, critically appraised the 
manuscript and approved the final version. 
 
12 Funding 
 
National Institute of Health Research Health Technology Assessment (NIHR HTA project 
code 11_129_109), and Swiss Heart Foundation. 
 
13 Data sharing 
 
13.1 Data sharing 
Once completed, individual patient data from TICH-2 will be made available to the ‘Virtual 
International Stroke Trials Archive’ (VISTA), and subsequently over the web, as with the 
International Stroke Trial. Similarly, anonymised baseline and on-treatment neuroimaging 
data will be published. After publication of the planned primary and secondary analyses, the 
trial data may be shared, upon reasonable request to the corresponding author and trial 
steering committee. 
 
14 Publications 
 
14.1 Primary publication 
Sprigg N, Flaherty K, Appleton JP, Salman RA, Bereczki D, Beridze M, Christensen H, 
Ciccone A, Collins R, Czlonkowska A, Dineen RA. Tranexamic acid for hyperacute primary 
IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 
3 superiority trial. The Lancet. 2018 May 16. 
Sections of this report are reproduced from the Lancet article "Tranexamic acid for hyperacute 
primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, 
phase 3 superiority trial"  https://doi.org/10.1016/S0140-6736(18)31033-X 
 and is available under the terms of the Creative Commons Attribution License (CC BY) 
https://creativecommons.org/licenses/by/4.0/# 
 
 
 68 
14.2 Published protocol 
Sprigg N, Robson K, Bath P, Dineen R, Roberts I, Robinson T, Roffe C, Werring D, Al-
Shahi Salman R, Pocock S, Duley L. Intravenous tranexamic acid for hyperacute primary 
intracerebral hemorrhage: protocol for a randomized, placebo-controlled trial. 
 
14.3 Statistical analysis plan 
Flaherty K, Bath PM, Dineen R, Law Z, Scutt P, Pocock S, Sprigg N. Statistical analysis plan 
for the ‘Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage’(TICH-2) trial. 
Trials. 2017 Dec;18(1):607. 
 
14.4 Protocol for MRI sub-study 
Dineen RA, Pszczolkowski S, Flaherty K, Law ZK, Morgan PS, Roberts I..... Sprigg N, 
(2018). Does tranexamic acid lead to changes in MRI measures of brain tissue health in 
patients with spontaneous intracerebral haemorrhage? Protocol for an MRI substudy nested 
within the double-blind randomised controlled TICH-2 trial. BMJ open, 8 (2), pp. e019930 
 
14.5 TICH-1 primary publication 
Sprigg N, Renton CJ, Dineen RA, Kwong Y, Bath PM. (2014). Tranexamic acid for 
spontaneous intracerebral hemorrhage: a randomized controlled pilot trial 
(ISRCTN50867461). Journal of stroke and cerebrovascular diseases: the official journal of 
National Stroke Association, 23 (6), pp. 1312-8 
 
14.6 Statistical analysis plan for pre-specified spot sign sub-study 
Ovesen C, Jakobsen JC, Gluud C, Steiner T, Law Z, Flaherty K..... Christensen H, (2018). 
Prevention of haematoma progression by tranexamic acid in intracerebral haemorrhage 
patients with and without spot sign on admission scan: a statistical analysis plan of a pre-
specified sub-study of the TICH-2 trial. BMC research notes, 11 (1), pp. 379 
 
14.7 Cochrane Review of Haemostatic Therapies 
Rustam Al-Shahi Salman, Zhe Kang Law, Bath PM, et al. Haemostatic therapies for acute 
spontaneous intracerebral haemorrhage. Cochrane Database of Systematic Reviews. John 
Wiley & Sons, Ltd, 2018 
  
 69 
15 References 
 
1. van Asch CJ, Luitse MJ, Rinkel GJ, et al. Incidence, case fatality, and functional 
outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a 
systematic review and meta-analysis. The Lancet Neurology 2010; 9: 167-176. 2010/01/09. 
DOI: 10.1016/s1474-4422(09)70340-0. 
2. Brott T, Broderick J, Kothari R, et al. Early hemorrhage growth in patients with 
intracerebral hemorrhage. Stroke 1997; 28: 1-5. Article. 
3. Davis SM, Broderick J, Hennerici M, et al. Hematoma growth is a determinant of 
mortality and poor outcome after intracerebral hemorrhage. Neurology 2006; 66: 1175-1181. 
DOI: 66/8/1175 [pii] 
10.1212/01.wnl.0000208408.98482.99. 
4. Demchuk AM, Dowlatshahi D, Rodriguez-Luna D, et al. Prediction of haematoma 
growth and outcome in patients with intracerebral haemorrhage using the CT-angiography 
spot sign (PREDICT): a prospective observational study. The Lancet Neurology 2012; 11: 
307-314. 2012/03/13. DOI: 10.1016/s1474-4422(12)70038-8. 
5. Anderson CS, Huang Y, Arima H, et al. Effects of early intensive blood pressure-
lowering treatment on the growth of hematoma and perihematomal edema in acute 
intracerebral hemorrhage: the Intensive Blood Pressure Reduction in Acute Cerebral 
Haemorrhage Trial (INTERACT). Stroke 2010; 41: 307-312. 2010/01/02. DOI: 
10.1161/strokeaha.109.561795. 
6. Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients 
with acute intracerebral hemorrhage. N Engl J Med 2013; 368: 2355-2365. 2013/05/30. DOI: 
10.1056/NEJMoa1214609. 
7. Steiner T, Al-Shahi Salman R, Beer R, et al. European Stroke Organisation (ESO) 
guidelines for the management of spontaneous intracerebral hemorrhage. International 
journal of stroke : official journal of the International Stroke Society 2014; 9: 840-855. 
2014/08/27. DOI: 10.1111/ijs.12309. 
8. Hemphill JC, 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the Management 
of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From 
the American Heart Association/American Stroke Association. Stroke 2015; 46: 2032-2060. 
2015/05/30. DOI: 10.1161/str.0000000000000069. 
 70 
9. Qureshi AI, Palesch YY, Barsan WG, et al. Intensive Blood-Pressure Lowering in 
Patients with Acute Cerebral Hemorrhage. N Engl J Med 2016; 375: 1033-1043. DOI: 
doi:10.1056/NEJMoa1603460. 
10. Anderson CS, Selim MH, Molina CA, et al. Intensive Blood Pressure Lowering in 
Intracerebral Hemorrhage. Stroke 2017; 48: 2034-2037. 2017/06/20. DOI: 
10.1161/strokeaha.117.016185. 
11. Law ZK, Appleton JP, Bath PM, et al. Management of acute intracerebral 
haemorrhage - an update. Clinical medicine (London, England) 2017; 17: 166-172. 
2017/04/04. DOI: 10.7861/clinmedicine.17-2-166. 
12. Whelton PK, Carey RM, Aronow WS, et al. 2017 
ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the 
Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. 
Journal of the American College of Cardiology 2018; 71: e127-e248. DOI: 
10.1016/j.jacc.2017.11.006. 
13. Intercollegiate Stroke Working Party. National clinical guideline for stroke. Fifth ed. 
London: Royal College of Physicians, October 2016. 
14. van Loon J, Van Calenbergh F, Goffin J, et al. Controversies in the management of 
spontaneous cerebellar haemorrhage. A consecutive series of 49 cases and review of the 
literature. Acta neurochirurgica 1993; 122: 187-193. 1993/01/01. 
15. Kirollos RW, Tyagi AK, Ross SA, et al. Management of spontaneous cerebellar 
hematomas: a prospective treatment protocol. Neurosurgery 2001; 49: 1378-1386; discussion 
1386-1377. 2002/02/16. 
16. Adams RE and Diringer MN. Response to external ventricular drainage in 
spontaneous intracerebral hemorrhage with hydrocephalus. Neurology 1998; 50: 519-523. 
1998/03/04. 
17. Mendelow AD, Gregson BA, Fernandes HM, et al. Early surgery versus initial 
conservative treatment in patients with spontaneous supratentorial intracerebral haematomas 
in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. 
Lancet (London, England) 2005; 365: 387-397. 2005/02/01. DOI: 10.1016/s0140-
6736(05)17826-x. 
18. Mendelow AD, Gregson BA, Rowan EN, et al. Early surgery versus initial 
conservative treatment in patients with spontaneous supratentorial lobar intracerebral 
haematomas (STICH II): a randomised trial. Lancet (London, England) 2013; 382: 397-408. 
2013/06/04. DOI: 10.1016/s0140-6736(13)60986-1. 
 71 
19. Steiner T, Poli S, Griebe M, et al. Fresh frozen plasma versus prothrombin complex 
concentrate in patients with intracranial haemorrhage related to vitamin K antagonists 
(INCH): a randomised trial. The Lancet Neurology 2016; 15: 566-573. 2016/06/16. DOI: 
10.1016/s1474-4422(16)00110-1. 
20. Pollack CV, Jr., Reilly PA, Eikelboom J, et al. Idarucizumab for Dabigatran Reversal. 
N Engl J Med 2015; 373: 511-520. 2015/06/23. DOI: 10.1056/NEJMoa1502000. 
21. Connolly SJ, Milling TJJ, Eikelboom JW, et al. Andexanet Alfa for Acute Major 
Bleeding Associated with Factor Xa Inhibitors. N Engl J Med 2016; 375: 1131-1141. DOI: 
doi:10.1056/NEJMoa1607887. 
22. Mayer SA, Brun NC, Broderick J, et al. Safety and feasibility of recombinant factor 
VIIa for acute intracerebral hemorrhage. Stroke 2005; 36: 74-79. 
23. Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant activated 
factor VII for acute intracerebral hemorrhage. N Engl J Med 2008; 358: 2127-2137. 
2008/05/16. DOI: 10.1056/NEJMoa0707534. 
24. Al-Shahi Salman R, Law ZK, Bath PM, et al. Haemostatic therapies for acute 
spontaneous intracerebral haemorrhage. The Cochrane database of systematic reviews 2018; 
4: Cd005951. 2018/04/18. DOI: 10.1002/14651858.CD005951.pub4. 
25. NCT00810888. The Spot Sign for Predicting and Treating ICH Growth Study. 
https://clinicaltrials.gov/ct2/show/NCT01359202, 2008. (Accessed Sept 13 2018). 
26. Gladstone D and on behalf of the "SPOTLIGHT" investigators. ""Spot Sign" 
Selection of Intracerebral Hemorrhage to Guide Hemostatic Therapy (SPOTLIGHT)", 
(2011). 
27. Gladstone DJ. Randomized Trial of Hemostatic Therapy for 'Spot Sign' Positive 
Intracerebral Hemorrhage: Primary Results From the SPOTLIGHT/STOP-IT Study 
Collaboration. In: ISC 2017. 
28. Baharoglu MI, Cordonnier C, Salman RA, et al. Platelet transfusion versus standard 
care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet 
therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet (London, England) 2016; 
387: 2605-2613. 2016/05/15. DOI: 10.1016/s0140-6736(16)30392-0. 
29. Zehtabchi S, Abdel Baki SG, Falzon L, et al. Tranexamic acid for traumatic brain 
injury: a systematic review and meta-analysis. Am J Emerg Med 2014; 32: 1503-1509. 
2014/09/28. DOI: 10.1016/j.ajem.2014.09.023. 
30. Dewan Y, Komolafe EO, Mejia-Mantilla JH, et al. CRASH-3 - tranexamic acid for 
the treatment of significant traumatic brain injury: study protocol for an international 
 72 
randomized, double-blind, placebo-controlled trial. Trials 2012; 13: 87. 2012/06/23. DOI: 
10.1186/1745-6215-13-87. 
31. WOMAN Trial Collaborators. Effect of early tranexamic acid administration on 
mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage 
(WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet 
(London, England) 2017; 389: 2105-2116. 2017/05/01. DOI: 10.1016/s0140-6736(17)30638-
4. 
32. Gayet-Ageron A, Prieto-Merino D, Ker K, et al. Effect of treatment delay on the 
effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of 
individual patient-level data from 40 138 bleeding patients. Lancet (London, England) 2018; 
391: 125-132. 2017/11/12. DOI: 10.1016/s0140-6736(17)32455-8. 
33. Baharoglu MI, Germans MR, Rinkel GJ, et al. Antifibrinolytic therapy for aneurysmal 
subarachnoid haemorrhage. The Cochrane database of systematic reviews 2013: Cd001245. 
2013/08/31. DOI: 10.1002/14651858.CD001245.pub2. 
34. Ojacastro MF, Tabuena MP, Dulos ID, et al. Efficacy of tranexamic acid in reducing 
hematoma volume in patients with hypertensive intracerebral hemorrhage. International 
journal of stroke : official journal of the International Stroke Society 2008; 3 Supp 1: S197-
198 [ABSTRACT]. Absract. DOI: 10.1111/j.1747-4949.2008.00231.x. 
35. Sorimachi T, Fujii Y, Morita K, et al. Rapid administration of antifibrinolytics and 
strict blood pressure control for intracerebral hemorrhage. Neurosurgery 2005; 57: 837-843. 
DOI: 10.1227/01.neu.0000180815.38967.57. 
36. Sorimachi T, Fujii Y, Morita K, et al. Predictors of hematoma enlargement in patients 
with intracerebral hemorrhage treated with rapid administration of antifibrinolytic agents and 
strict blood pressure control. Journal of neurosurgery 2007; 106: 250-254. 2007/04/07. DOI: 
10.3171/jns.2007.106.2.250. 
37. Sprigg N, Renton CJ, Dineen RA, et al. Tranexamic acid for spontaneous 
intracerebral hemorrhage: A randomized controlled pilot trial (ISRCTN50867461). Journal of 
Stroke and Cerebrovascular Diseases 2014; 23: 1312-1318. DOI: 
http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2013.11.007. 
38. Arumugam A, NA AR, Theophilus SC, et al. Tranexamic Acid as Antifibrinolytic 
Agent in Non Traumatic Intracerebral Hemorrhages. The Malaysian journal of medical 
sciences : MJMS 2015; 22: 62-71. 2016/03/24. 
 73 
39. Zhe Kang Law, Atte Meretoja, Stefan T Engelter, et al. Treatment of intracerebral 
haemorrhage with tranexamic acid – A review of current evidence and ongoing trials. 
European Journal of Stroke 2016; 2: 13-22. DOI: 10.1177/2396987316676610. 
40. Horrow JC, Van Riper DF, Strong MD, et al. The dose-response relationship of 
tranexamic acid. Anesthesiology 1995; 82: 383-392. 1995/02/01. 
41. National Institute of Health NIoNDaSSShwnngdNSSp. 
http://www.ninds.nih.gov/doctors/NIH_Stroke_Scale.pdf. (Accessed Sept 13 2018). 
42. Mahoney FI and Barthel DW. Functional evaluation: The Barthel Index. Maryland 
State Medical Journal 1965: 61-65. 
43. Bath PM, Lees KR, Schellinger PD, et al. Statistical analysis of the primary outcome 
in acute stroke trials Stroke 2012; 43: 1171-1178. 
44. Euroqol Group. EuroQol--a new facility for the measurement of health-related quality 
of life. The EuroQol Group. Health Policy 1990; 16: 199-208. 
45. de Jager CA, Budge MM and Clarke R. Utility of TICS-M for the assessment of 
cognitive function in older adults. International Journal of Geriatric Psychiatry 2003; 18: 
318-324. 
46. Zung WWK. A self-rating depression scale. Arch Gen Psychiatry 1965; 12: 63-70. 
47. The Optimising Analysis of Stroke Trials (OAST) Collaboration. Should stroke trials 
adjust functional outcome for baseline prognostic factors? Stroke 2009; 40: 888-894. DOI: 
10.1161/STROKEAHA.108.519207. 
48. Ker K, Prieto-Merino D, Sprigg N, et al. The effectiveness and safety of 
antifibrinolytics in patients with acute intracranial haemorrhage: statistical analysis plan for 
an individual patient data meta-analysis. Wellcome Open Research 2017; 2: 120. DOI: 
10.12688/wellcomeopenres.13262.2. 
49. Al-Shahi Salman R, Frantzias J, Lee RJ, et al. Absolute risk and predictors of the 
growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-
analysis of individual patient data. The Lancet Neurology 2018. DOI: 10.1016/S1474-
4422(18)30253-9. 
50. Donnan G, Davis S and Zhao H. STOP-MSU: Stopping Haemorrhage With 
Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units, 
https://clinicaltrials.gov/ct2/show/NCT03385928. (Accessed Sept 13 2018). 
51. Davis SM, Donnan GA and on behalf of the STOP-AUST investigators. STOP-
AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - Australasia Trial. 
 74 
52. Woo PY. Tranexamic Acid for Spontaneous Acute Cerebral Hemorrhage Trial 
(TRANSACT), https://clinicaltrials.gov/ct2/show/NCT03044184 (2017, 2017). (Accessed 
Sept 13 2018). 
53. Lyrer P, Peters N and Seiffge D. TICH-NOAC; ClinicalTrials.gov Identifier: 
NCT02866838, (2016, 2017). (Accessed Sept 13 2018). 
54. Liu L. Tranexamic Acid for Acute ICH Growth prEdicted by Spot Sign (TRAIGE), 
https://clinicaltrials.gov/ct2/show/NCT02625948?term=TRANEXAMIC+ACID&cond=ICH
&rank=2 (2016, 2017). (Accessed Sept 13 2018). 
55. Seiffge D, Peters N, Sprigg N, et al. Treatment of intracerebral hemorrhage in patients 
on direct oral anticoagulants with tranexamic acid-TICH-DOAC. International Journal of 
Stroke 2015; 10: 76. Conference Abstract. DOI: http://dx.doi.org/10.1111/ijs.12478. 
56. Al-Shahi Salman R, Dennis MS, Murray GD, et al. The REstart or STop 
Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral 
haemorrhage: study protocol for a randomised controlled trial. Trials 2018; 19: 162. journal 
article. DOI: 10.1186/s13063-018-2542-6. 
57. Roberts I, Belli A, Brenner A, et al. Tranexamic acid for significant traumatic brain 
injury (The CRASH-3 trial): Statistical analysis plan for an international, randomised, 
double-blind, placebo-controlled trial Wellcome Open Research 2018; 3. 
58. Park JJH, Thorlund K and Mills EJ. Critical concepts in adaptive clinical trials. 
Clinical Epidemiology 2018; 10: 343-351. DOI: 10.2147/CLEP.S156708. 
59. Goobie SM. Tranexamic acid: still far to go. British Journal of Anaesthesia 2017; 
118: 293-295. DOI: 10.1093/bja/aew470. 
60. Donnan G, Davis S and Henry Z. STOP-MSU: Stopping Haemorrhage With 
Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units. 
https://clinicaltrials.gov/ct2/show/NCT03385928 
, (2018, accessed Jan 29th 2019). 
61. Berge E, Al-Shahi Salman R, van der Worp HB, et al. Increasing value and reducing 
waste in stroke research. The Lancet Neurology 2017; 16: 399-408. 2017/04/18. DOI: 
10.1016/s1474-4422(17)30078-9. 
 
 
 
 
 75 
16 Appendices  
 
16.1 Appendix 1: Full list of protocol amendments: 
3 December 2012 - The protocol had to be amended following REC review. The changes 
relate to participant identifiers and the consent process for potential participants who are not 
able to consent for themselves and do not have relatives present.  
9 October 2013 Update to Part B Section 3 (Radiation) on the REC and R&D Form 
28 February 2014 – 5 amendments: 
Amendment 1 – extension to follow up period. We expected that most patients would 
continue to improve following their stroke, and that we may miss important changes in 
recovery by only following patients up to day 90. Therefore, the follow-up period was 
extended to day 365. 
Amendment 2 – temperature monitoring – the protocol was updated to reflect the SmPC. 
Amendment 3 - co–enrolment to the RESTART study. This allowed enrolment into both 
studies, as long as co-enrolment did not affect the safety of participants, or the quality of the 
scientific data and allowed both important clinical questions to be answered. 
Amendment 4 – clarification of consent procedures in the emergency situation. 
Amendment 5 – to make typographical changes where required. 
4 March 2015 - addition of MRI sub study.  
24 July 2015 - Update to MRI sub study consent forms – to include missing initial box and 
remove participant signature line on personal legal representative consent form as participant 
would not sign this form. 
9 November 2015 - Minor amendment to MRI sub study consent forms 
26 May 2016 - Addition of plasma biomarkers sub study in one centre. 
1 September 2016 – To apply for 12 month extension to recruitment with recruitment planned 
to be completed September 2017 and grant closure February 2018. 
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16.2 Appendix 2: Definition of safety events 
A. Acute coronary syndrome (ACS) 
Unstable Angina  
Although there is no universally accepted definition of unstable angina, it has been described 
as a clinical syndrome between stable angina and acute myocardial infarction.  
Myocardial infarction (MI) 
Either one of the following criteria satisfies the diagnosis for an acute, evolving or recent MI:  
1. Typical rise and gradual fall (troponin) or more rapid rise and fall (CK-MB) of 
biochemical markers of myocardial necrosis with at least one of the following:  
• ischaemic symptoms;  
• development of pathologic Q waves on the ECG;  
• ECG changes indicative of ischemia (ST segment elevation or depression); or  
• Coronary artery intervention (e.g. coronary angioplasty).  
2. Pathologic findings of an acute MI. 
B. Ischaemic stroke  
A clinical syndrome characterised by rapidly developing clinical symptoms and/or signs of 
focal (and at times global) loss of cerebral function with symptoms lasting for more than 24 
hours or leading to death, with no apparent cause other than that of vascular origin. 
Classification as ischaemic is based on results of head CT/MRI imaging excluding 
haemorrhage. 
C. Transient ischaemic attack (TIA) 
A sudden focal neurological deficit of the brain or eye, presumed to be of vascular origin and 
lasts less than 24 hours. 
D. Peripheral arterial disease (PAD) 
A sudden blockage of a peripheral artery; the blockage may result from a blood clot, 
embolism, dissection or trauma. Symptoms usually start suddenly. Acute peripheral arterial 
limb occlusion includes the 7 symptoms listed below:  
1. Severe pain  
2. Coldness  
3. Paraesthesia  
4. Loss of sensation  
5. Paleness in an extremity  
6. Lack of pulse in an extremity  
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7. Blue skin in affected limb. It can also affect the arteries that carry blood from the 
kidneys and stomach.  
Examples of evidence required;  
• Clinical  
• Radiological details e.g. angiogram 
 
E. Seizure/ convulsions  
Focal or generalised seizures, tonic-clonic seizures or partial seizures; diagnosed clinically 
after review by an appropriately trained physician. 
F. Venous thromboembolism (VTE) 
This encompasses both deep vein thrombosis (DVT) and pulmonary embolism (PE).  
Examples of evidence required;  
Clinical detail and  
DVT: 
• Ultrasound  
• Venography  
PE: 
• VQ (Ventilation Perfusion) Scan  
• CTPA (CT Pulmonary Angiogram) scan 
 
 
